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Abstract 
Polypharmacy, generally defined as taking five or more medications, is the leading cause of 
adverse drug events for older patients and affects as many as 95% of patients residing in long-
term care. Nearly half of all patients nearing the end of their life takes ten or more medications 
per day. Deprescribing is the systematic reduction of inappropriate, unnecessary, or harmful 
medications by healthcare providers. Goals for deprescribing include improved patient outcomes, 
increased patient satisfaction, and enhanced patient safety. The purpose of this quality 
improvement project was to develop a systematic approach to medication reduction through 
deprescribing. The target population was hospice patients who reside in long-term care, as this 
patient population is at the highest risk for polypharmacy and adverse drug events. The project 
author educated the long-term care facility providers and pharmacists on the prevalence of 
polypharmacy and the benefits of deprescribing for this vulnerable population. Through 
interagency collaboration, the hospice nurse practitioner, hospice nurse, and facility pharmacist 
developed a system of regular medication reviews for the target patient population. This 
multidisciplinary team then made recommendations for deprescribing to the facility physician 
and nurse practitioner. The Doctor of Nursing Practice student collected data at regular intervals 
throughout the project implementation regarding the number of medications prescribed to each 
hospice patient. The outcome goal was a ten percent reduction in medications for hospice 
patients living in long-term care. Project outcomes showed a decrease in medications of sixteen 
percent from initial data collection to the end of the project.  
Key words: deprescribing, polypharmacy, long-term care, hospice, end of life 
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Chapter One:  Overview of the Problem of Interest  
 Polypharmacy, defined as taking five or more medications (McNeil, Kamal, Kutner, 
Ritchie, & Abernethy, 2016), is the most common cause of adverse drug events (ADEs) for older 
patients, particularly those who reside in long-term care (LTC) facilities (Palagyi, Keay, Harper, 
Potter, & Lindley, 2016). Studies show that nearly half of patients who are nearing the end of life 
take ten or more medications (Morin, Vetrano, et al., 2017). Polypharmacy reduces perceived 
quality of life in the elderly population due to pill burden, early satiety, and medication side 
effects due to altered pharmacokinetics and pharmacodynamics (Morin, Vetrano, et al., 2017). 
The financial burden of polypharmacy extends to the cost of adverse events such as falls, 
hospitalization, and premature death (McGrath, Hajjar, Kumar, Hwang, & Salzman, 2017). 
Deprescribing, defined as the systematic reduction of inappropriate or unnecessary medications 
by a healthcare professional, leads to a decrease of ADEs, unwanted side effects, and financial 
burden, and improves outcomes for patients with life-limiting illness who reside in LTC (Reeve, 
Gnjidic, Long, & Hilmer, 2015).  
Background Information  
 Problem identification. Polypharmacy is associated with adverse outcomes for patients 
of all ages and in all settings, but the frequency of ADEs nearly doubles for older patients 
residing in LTC (Garfinkel, Ilhan, & Bahat, 2015). Palagyi et al. (2016) note that patients who 
live in long-term care facilities comprise a “frail population with often complex health 
conditions” (Background section, para. 1), leading to polypharmacy for as many as 95% of these 
residents. Patients at the end of life are more likely to have an increased pill burden due to the 
accumulation of medications for the prevention of illness, treatment of acute and chronic 
diseases, and those prescribed for symptom management (McNeil et al., 2016). Garfinkel et al. 
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(2015) use the term inappropriate medication use (IMU) interchangeably with polypharmacy. 
They note that the number of medications prescribed to a patient may increase due to a 
prescription cascade, where prescribers give patients additional medications to combat the side 
effects of drugs they are already taking. There may also be a duplication of therapy that results 
from multiple specialists treating patients with complex and comorbid conditions (Garfinkel et 
al., 2015). Elderly patients with polypharmacy are nearly 20% more likely to be hospitalized for 
drug-related issues and have double the incidence of cognitive impairment when compared to 
patients taking less than five medications (Garfinkel et al., 2015). Palagyi et al. found that, for 
patients over the age of 75, medication-related events comprised 30% of all emergent hospital 
admissions, further compounding the issue of polypharmacy for those patients.   
Quality of life is a crucial factor when evaluating IMU and polypharmacy, particularly 
for patients at the end of life who reside in long-term care. Patients with polypharmacy report 
poor quality of life related to pill burden and anxiety due to a higher risk of falls (Garfinkel et al., 
2015). Morin, Todd, et al. (2019) note that terminally ill patients often take preventative 
medications into the last month of life, including antihypertensives, anticoagulants, statin 
medications, and oral hypoglycemics. The continuation of maintenance medications leads to a 
30% increase in the average number of drugs taken in the final year of life and the proliferation 
of polypharmacy (Morin, Todd, et al., 2019). The financial burden of polypharmacy for patients 
with a terminal cancer diagnosis can be as high as $490 per patient for preventative medications 
alone (Morin, Todd, et al., 2019).    
 Description of problem. Deprescribing has emerged as a process of systematically 
identifying and discontinuing medications that are no longer necessary, effective, or appropriate 
to mitigate their negative impact on patient outcomes and quality of life (McGrath et al., 2017). 
DEPRESCRIBING FOR HOSPICE PATIENTS IN LONG-TERM CARE                           12 
Deprescribing is a new phenomenon that is undergoing metamorphosis but is grounded in 
evidence-based research. Systematic reviews and meta-analysis of the concept have shown that 
patients who take fewer medications have improved cognition, reduced incidence of falls, and 
reduced ADEs while enjoying an increase in survival rates, medication adherence, and improved 
patient satisfaction (McGrath et al., 2017). Also, deprescribing reduces health care costs without 
increasing morbidity and mortality (McGrath et al., 2017). 
  Providing quality care for patients nearing the end of life is the mission of a non-profit 
hospice agency in southwestern North Carolina (NC). On average, 5% of the patients served by 
this agency reside in LTC facilities. These patients remain under the care of the facility provider, 
who may or may not have experience in end-of-life care. According to the independent 
pharmacy provider for the hospice agency, patients who reside in long-term care under hospice 
services take an average of 12 medications each, which is nearly twice that of patients living at 
home. Hospice providers do not have prescriptive authority in these facilities, and patients 
continue to bear the risk of ADEs and poor outcomes associated with polypharmacy.  
Goals for deprescribing include improved patient outcomes, increased patient 
satisfaction, and enhanced patient safety for this specific patient population. As a non-profit 
community agency, the hospice organization must be diligent in maximizing cost savings 
wherever possible. The hospice agency currently pays a per diem rate for services provided by a 
contracted pharmacy based on each patient’s medication profile. The reduction of inappropriate 
medications through deprescribing will offer savings to the organization through lower 
medication costs. Medication reduction also provides leverage for negotiating lower per diem 
rates with the pharmacy provider with a potential for as much as $5,000 in annual cost savings. 
The hospice agency and the long-term care facility may realize further cost savings with the 
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reduction of ADEs, including falls and unnecessary hospitalizations. The reduction of 
medications for this vulnerable population aligns with the goals of the Healthy People 2020 
initiative to reduce the number of medicines taken by disabled older adults (U.S. Department of 
Health and Human Services [HHS], 2019). Finally, The Institute for Healthcare Improvement’s 
(IHI) triple aim calls for improvement of the health of the general population, increased patient 
satisfaction with healthcare, and cost reduction, which is all accomplished through deprescribing 
(IHI, 2019b).    
Significance of Clinical Problem  
 The purpose of this project is to reduce the number of medications prescribed for patients 
at the end of life who reside in LTC. Polypharmacy is a causative factor for ADEs, particularly 
for this vulnerable population. There is a sense of urgency to identify and eliminate 
inappropriate, unnecessary, and ineffective medications for patients under the care of hospice 
services who reside in LTC. Deprescribing is a useful tool to achieve improved patient outcomes, 
provide cost savings for both the hospice organization and the LTC facility, and adhere to 
government goals and maintain facility compliance with regulatory mandates.  
Currently, there is no mechanism for collaboration between the facility providers and 
pharmacists and hospice providers. Patients and community partner organizations benefit from 
the development of an interagency, multidisciplinary, collaborative team focused on medication 
deprescribing. This project will provide a low-cost, high impact program that will be sustainable 
and reproducible for use in facilities and organizations beyond the project focus.  
Question Guiding Inquiry (PICO)  
An independent, non-profit hospice organization in southwestern NC has identified that 
their patients who reside in LTC are currently prescribed twice the number of medications, on 
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average, as homecare patients. These patients are at risk for ADEs related to polypharmacy. 
Additionally, the hospice organization and LTC facility bear the costs associated with the 
purchase and dispensing of medications used by their mutual patients. This cost may be higher 
than necessary if patients take medicines that are unnecessary or inappropriate. The hospice 
organization is interested in developing an educational program on deprescribing that facilitates 
collaboration and communication between the facility providers and pharmacist and hospice 
providers. The goal of this collaboration is to establish a system of appropriate deprescribing for 
hospice patients residing in LTC and reduce the number of medications prescribed to patients 
nearing the end of life in these facilities. 
 Population. The population selected for this project included the physician, nurse 
practitioner, and pharmacists who are employed by the LTC facility. The physician and nurse 
practitioner have prescribing privileges, and the pharmacist conducts medication reviews as a 
regular part of her workday. These healthcare professionals are experts in long-term care but do 
not necessarily have experience in end of life care.  
Intervention. The intervention was an educational session in which the hospice provider 
presented evidence-based research on the risks of polypharmacy and the benefits of 
deprescribing. The DNP student gave the presentation at the LTC facility, with a light snack 
provided for participants. Each participant received a professionally bound resource manual 
containing the information presented at the session in addition to a guideline for deprescribing 
and contact information for the presenter. Participants were given a project data collection tool at 
the start and conclusion of the educational session to assess each participant’s willingness to 
deprescribe based on the information presented.  
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Comparison. Currently, hospice patients who reside in LTC facilities are prescribed 
twice the number of medications as homecare patients, according to the pharmacy vendor 
contracted by the hospice organization. Greater than 90% of all the patients under the care of the 
hospice organization have medication regimens that qualify as polypharmacy. Healthy People 
2020 had a goal of a 10% reduction of inappropriate medications for disabled older adults (HHS, 
2019). The IHI (2019b) Triple Aim addressed improved experience with healthcare while 
improving the health of a population and reducing the costs of healthcare. This project assisted 
the facility providers and pharmacist in identifying medications that were appropriate for 
deprescribing and facilitated the LTC agency in complying with governmental mandates and 
goals. This DNP project also contributed to risk avoidance and financial benefit related to a 
reduction in ADEs and their associated costs. Finally, medication reduction through 
deprescribing has the potential to promote cost savings for the hospice organization through both 
a decrease in the number of medications provided and contracted savings with the pharmacy 
vendor.  
Outcomes. The benefit of the successful implementation of this project was three-fold: 
First, it demonstrated a 10% reduction in unnecessary, inappropriate, or ineffective medications 
for the hospice patient residing in the LTC facility. The reduction of polypharmacy leads to 
improved patient satisfaction, perceived improvement in quality of life, and avoidance of 
unnecessary suffering related to ADEs. Second, the project strengthened community partnerships 
and provided for interagency/interprofessional collaboration. Finally, the project assisted the 
LTC facility and the hospice agency in meeting government goals set forth by the IHI and 
Healthy People 2020 and contributed to overall cost savings related to the reduction in 
medications and ADEs.   
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Summary  
 Polypharmacy and deprescribing are essential concepts for patients who are at the end of 
life, particularly for the long-term care population. Polypharmacy, described as taking five or 
more medications, predisposes patients to a higher risk of adverse drug events, including falls, 
cognitive impairment, unplanned hospitalization, and premature death. Deprescribing is a 
systematic reduction of unnecessary, inappropriate, or ineffective medications. There is a 
growing body of evidence regarding the importance of deprescribing, particularly for patients 
with complex health issues who are nearing the end of life. Reducing medications leads to 
improved quality of life by minimizing pill burden and reducing drug to drug interactions. The 
reduction of ADEs benefits the patient through risk avoidance and the facility through cost 
savings. A well-structured, evidence-based presentation offered to facility providers and 
pharmacists on deprescribing for patients residing in LTC who are at the end of life provided a 
platform for interprofessional collaboration.  A project data collection tool assessed the 
willingness of project participants to deprescribe identified specific medication categories 
appropriate for deprescribing and developed a channel for ongoing communication and 
education between the participating agencies. The project goal was to educate 100% of the LTC 
facility providers and pharmacists, with a secondary goal of a 10% reduction in unnecessary 
medications prescribed to hospice patients residing in the LTC facility. The benefits of the 
project included cost savings and regulatory compliance for the LTC facility through a reduced 
number of ADEs and cost savings for the hospice organization through a reduction in the actual 
number of medications purchased for our mutual patients. The real winner in this project is the 
patient, who will realize improved outcomes and a better quality of life as a result of appropriate 
deprescribing.   
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Chapter Two:  Review of the Literature  
The foundation of effective change in healthcare is to identify gaps for which there is 
clear evidence of need followed by specific interventions with demonstrated benefit to address 
the deficit. Polypharmacy, defined as taking five or more medications, has been shown to affect 
over 80% of patients aged 65 or older residing in LTC (Paque, Elseviers, et al., 2019). The goal 
of deprescribing for patients who live in LTC facilities and are under hospice care is to improve 
quality of life for the patient, reduce the risk of ADEs, and reduce costs for the facility and the 
hospice organization.  
A comprehensive literature search revealed the current body of knowledge regarding 
polypharmacy and deprescribing, specifically as it applies to patients who are nearing the end of 
life and reside in LTC. There is a rich body of research documenting the significant risks 
associated with unnecessary and inappropriate medication use, yet guidelines for deprescribing 
are just beginning to emerge in the literature. The most complex patients, including LTC patients 
in hospice, pose additional challenges for deprescribing. There is currently no consensus as to the 
most appropriate way to achieve medication reduction for this population. 
Literature Appraisal Methodology  
Sampling strategies.  Using East Carolina University’s Laupus Health Science library’s 
one-search feature, the author searched PubMed, Cumulative Index of Nursing and Allied Health 
Literature (CINAHL), and Google Scholar databases. The terms polypharmacy, deprescribing, 
medication reduction, guidelines, preventative medications, inappropriate medications, end of 
life, hospice, long term care, and nursing home were used for the initial search, yielding 4,279 
items, 3,525 of which were journal articles. The author narrowed the search using medical 
subject headings (MeSH) terms including medicine, pharmacy, therapeutics, pharmacology, 
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public health, nursing, and anatomy/physiology and further restricted using criteria of 
scholarly/peer reviews and English language, with 268 items remaining. The final criteria used to 
limit the search was five-year recency, yielding 180 publications. Ongoing search strategies 
include the use of PubMed’s NCBI for relevant resources to be sent to the provided email 
address. 
Evaluation criteria. The author used the preferred reporting items for systematic reviews 
and meta-analysis (PRISMA) model to organize publications for inclusion and exclusion in the 
literature review (Moher, Liberati, Tetzaff, & Altman, 2009). In addition to the 180 articles 
found in the search described above, there were 18 publications included from other sources. In 
all, there were eight duplicate articles, for a total of 190 articles that met the criteria for 
screening. Of these 190 articles, 143 were excluded based on title and abstract, with exclusion 
criteria focusing on participants residing in the community rather than LTC. Some studies were 
excluded based on their focus on community primary care providers instead of providers caring 
for patients in facilities. Of the 47 articles remaining, 22 were too narrowly focused on a single 
disease process, specific adverse events, or attitudes of members of the healthcare team and 
therefore excluded. The project author excluded four articles that were study protocols for 
incomplete research. A total of 21 articles met the criteria for inclusion in the literature review, 
with the focus on patients residing in LTC with life-limiting disease and polypharmacy (see 
Appendix A).  
Next, the author sorted articles by the strength of evidence using Melnyk Levels of 
Evidence (Melnyk & Fineout-Overholt, 2015). The highest level of evidence, denoted as level 1, 
is reserved for systematic reviews and meta-analysis of randomized controlled trials (RCTs) 
(Melnyk & Fineout-Overholt, 2015). Subsequent levels of evidence include level 2 indicating a 
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study based on one or more RCTs, level 3 denoting controlled trials without randomization, and 
level 4 evidence given to case-control or cohort studies (Melnyk & Fineout-Overholt, 2015). 
Systematic reviews of qualitative or descriptive studies are found in level-5 evidence, according 
to Melnyk and Fineout-Overholt (2015), with level 6 evidence given to a single qualitative or 
descriptive study. The final level of evidence, as described by Melnyk and Fineout-Overholt, is 
reserved for articles based on expert opinion.  
Of the 21 articles included in the literature review, two met the highest level of evidence, 
level 1, as systematic reviews with meta-analysis. One study was a controlled trial without 
randomization, which reached the evidence criteria for level 3. Two studies were level 4 
evidence, one a case-control, and one a cohort study. Six of the 21 articles selected were 
systematic reviews of qualitative studies, making them a level 5 for the strength of evidence. 
Five articles were based on a single qualitative or descriptive study, reflecting level 6 evidence, 
according to Melnyk and Fineout-Overholt. The last five articles, based on expert opinion, were 
assigned level 7 in the hierarchy of evidence (see Appendix B).   
Literature Review Findings  
The body of evidence surrounding polypharmacy and deprescribing has grown 
exponentially in the past several years. There are now systematic reviews and meta-analyses of 
multiple RCTs looking at polypharmacy in older patients, specifically those residing in long-
term care (Kua, Mak, & Lee, 2019; Page, Potter, Clifford, & Etherton-Beer, 2016). These 
patients often have complex health issues, multiple comorbid conditions, and are nearing the end 
of life. For this patient population, the correlation between polypharmacy and adverse drug 
events is well documented and reduces the quality of life (Schenker et al., 2019).  
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In their systematic review and meta-analysis on deprescribing for older residents of 
nursing homes, Kua et al. (2019) evaluated 41 RCTs looking at polypharmacy and associated 
adverse events, including mortality, falls and hospitalizations and the impact of deprescribing on 
patient outcomes. Fourteen studies included discontinuation of medications by various health 
care team members, namely physicians, pharmacists, and nurses. Eleven studies involved the use 
of evidence-based criteria, such as the Beers criteria, or tools such as the Screening Tool to Alert 
doctors to Right Treatment/Screening Tool of Older Person’s Prescriptions (START/STOPP) for 
medication reduction (Kua et al., 2019). The authors concluded that a systematic approach to 
deprescribing, whether done by providers or pharmacists, reduced the risk of ADEs for elderly 
patients residing in LTC (Kua et al., 2019).  
Deprescribing for the older population was the focus of the systematic review and meta-
analysis performed by Page, Potter, Clifford, and Etherton-Beer (2016). These researchers were 
interested in identifying a balance between the risks and benefits achieved through a systematic 
approach to deprescribing for this particularly vulnerable population (Page et al., 2016). The 
negative impact of polypharmacy found by the authors of this study included frailty, exhaustion, 
falls, cognitive impairment, disability, reduction in functional status, and death (Page et al., 
2016). The authors included a total of 116 studies in their review, with the findings reported as 
minimal adverse effects from deprescribing, with a reduction in the number of ADEs for patients 
taking few medications (Page et al., 2016).   
The controlled trial conducted by Farrell, Richardson, et al. (2018) utilized a survey to 
assess the effectiveness of evidence-based guidelines in assisting physicians, nurse practitioners, 
and pharmacists to develop the practice of deprescribing for their patients in LTC. Four surveys 
were distributed to the participants over time, with respondents indicating the level of 
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effectiveness the deprescribing guidelines had on their prescribing/deprescribing practice 
(Farrell, Richardson, et al., 2018). These authors concluded that offering prescribers guidelines 
for deprescribing assisted the individual clinician in developing a systematic approach to 
medication reduction (Farrell, Richardson, et al., 2018).  
One of the two studies that demonstrated level 4 strength of evidence included a cohort 
study that looked at prescribing practices for patients residing in LTC whose goals of care 
changed from prevention to symptom management (van der Meer, Taxis, & Pont, 2018). Their 
findings demonstrated little change in the number of medications taken by patients in the last 
year of life (van der Meer et al., 2018). While patients had a modest increase in medications 
prescribed for end of life symptoms, one-third of patients remained on preventative medicines at 
the time of death (van der Meer et al., 2018).  
The second level 4 study was a case-control study comparing the use of the Screening 
Tool of Older Persons Prescriptions in Frail adults with limited life expectancy (STOPPFrail) 
tool with systematic deprescribing done by trained geriatricians (Curtin, Jennings, et al., 2019). 
Using standardized clinical cases for older patients with multiple comorbidities, the authors 
compared the results of deprescribing completed by geriatric specialists to non-specialists 
utilizing the STOPPFrail tool (Curtin, Jennings, et al., 2019). The conclusion reached was that 
the STOPPFrail tool was a safe and effective alternative to consulting specialists to guide 
deprescribing in this patient population (Curtin, Jennings, et al., 2019). 
Six studies included in the literature review were systematic reviews of qualitative 
studies. The focus of each systematic review was unique but connected to the issues of 
polypharmacy, deprescribing, and hospice patients who reside in LTC. Farrell, Pottie, et al. 
(2016) looked at the efficacy for the use of a systematic 8-step process to develop evidence-
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based guidelines for deprescribing of class-specific medications. They concluded that the use of 
a systematic method to develop guidelines for discontinuing inappropriate medications reduces 
the risk of harm to the patient and aids the clinician in making complex clinical decisions 
regarding pharmacology (Farrell, Pottie, et al., 2016).  
Jokanovic, Tan, Dooley, Kirkpatrick, and Bell (2015) conducted an International, cross-
sectional systematic review looking at the frequency of polypharmacy for patients residing in 
LTC and subsequent outcomes related to medication usage. The authors found that up to 91% of 
patients living in LTC took five or more medications, with as many as 65% taking ten or more 
(Jokanovic et al., 2015). They concluded that, although there is a wide variation of polypharmacy 
depending on patient location, the larger the number of prescribed medications, the higher the 
risk for ADEs (Jokanovic et al., 2015).  
Paque, Vander Stichele, et al. (2019) conducted a systematic review of the literature to 
identify barriers and enablers associated with deprescribing for patients with a life-limiting 
disease. Five descriptive studies used in the analysis showed that reduced staffing and 
patient/family resistance to deprescribing were barriers to medication reduction (Paque, Vander 
Stichele, et al., 2019). Paque, Vander Stichele, and colleagues found that multidisciplinary teams 
and organizational support were the most significant enablers of deprescribing for the selected 
population.  
The use of preventative medications for patients nearing the end of life was the focus of a 
systematic review done by Poudel, Yates, Rowett, and Nissen (2017). Their investigation 
revealed that patients continue to be prescribed medications for reasons other than symptom 
management at the end of life (Poudel et al., 2017). They concluded that few rigorous studies 
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looked at the reduction of preventative medications for patients with life-limiting illness and 
called for further studies to address this gap in research (Poudel et al., 2017).   
One systematic review conducted by Thompson et al. (2019) looked at 15 different tools 
available for guiding clinicians in deprescribing medications for older patients with a life-
limiting illness. There were three distinctive types of tools, including a framework for 
deprescribing, an outline for a comprehensive evaluation of an entire medication list, and tools 
that were medication-specific (Thompson et al., 2019). The authors concluded that many of the 
instruments were developed using expert opinion or clinical experience, and only four have 
undergone clinical testing with low-quality studies, revealing the need for more rigorous studies 
to validate the outcomes of their use (Thompson et al., 2019).  
Todd et al. (2017) conducted a systematic review of qualitative studies looking at the 
prescribing of preventative medications for patients with life-limiting illnesses. The authors used 
the Beers criteria, STOPP criteria, Delphi consensus, and expert clinical opinion to assess the 
appropriateness of drugs prescribed to patients at the end of life (Todd et al., 2017). They found a 
lack of standardized guidelines for deprescribing of medications for patients with a limited life 
expectancy (Todd et al., 2017). Todd and his colleagues concluded that there is a need for 
guidelines to assist in deprescribing preventative medications for elderly patients with a life-
limiting illness.  
Six of the studies that met the criteria for inclusion in this literature review were single 
qualitative studies. Dees et al. (2018) conducted a survey of the perspectives of patients, family 
members, nurses, and providers regarding medication management at the end of life. The goal 
was to encourage patient-centered, multidisciplinary management of medications for patients 
with a life expectancy of three months or less (Dees et al., 2018). The authors concluded that 
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patient goals and preferences are central to effective medication management at the end of life 
and called for guidelines that incorporate a multidisciplinary, interdisciplinary approach to 
pharmacotherapy (Dees et al., 2018). 
McNeil, Kamal, Kutner, Ritchie, and Abernethy (2016) conducted a secondary analysis 
of a prospective trial looking at the number and types of medications prescribed to patients at the 
end of life. They found that patients with limited life expectancy took, on average, 10.7 
prescriptions at the time of their death (McNeil et al., 2016). The authors recognized that some of 
the medications were for symptom management, but that many were for the management of non-
life-threatening diseases (McNeil et al., 2016).  
Provider attitudes are crucial in successful medication reduction according to research on 
the barriers to deprescribing for patients in LTC (Palagyi, Keay, Harper, Potter, & Lindley, 
2016). The authors of this study conducted focus groups and interviews with nursing staff, 
patients, family members, pharmacists, and providers to uncover factors that inhibit the reduction 
of polypharmacy (Palagyi et al., 2016).  Palagyi and her colleagues concluded that provider 
attitudes are central to successful deprescribing for patients in LTC, as is education to promote 
acceptance of medication reduction by patients and their families.  
Assessing the risks and benefits of medications taken by patients who reside in LTC and 
have a life-limiting illness will lead to appropriate deprescribing and improve quality of life, 
according to Paque, Elseviers, et al. (2019). In this study, the STOPPFrail criteria were employed 
for deprescribing for patients nearing the end of life who reside in LTC (Paque, Elseviers, et al., 
2019). The authors concluded that, although overall medication usage remained high, patients for 
whom deprescribing occurred saw a reduction in the use of potentially inappropriate medications 
(Paque, Elseviers, et al., 2019). 
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Schenker et al. (2019) developed a secondary analysis of medication data from an RTC 
on the discontinuation of statin medications. The authors of this study focused on the correlation 
between polypharmacy, symptoms, and quality of life for patients with life-limiting illnesses 
(Schenker et al., 2019). The result of the analysis showed that, for patients who are nearing the 
end of life, polypharmacy contributes to significant symptom burden and reduced quality of life 
(Schenker et al., 2019). They concluded that there must be a focus on the symptoms caused by 
medications and a collaboration between health care providers and patients to reduce 
polypharmacy and improve quality of life (Schenker et al., 2019). 
The final five studies that met the criteria for inclusion in this literature review are the 
lowest level of evidence-based on expert opinion or consensus. Conklin, Farrell, and Suleman 
(2019) wrote about the challenges and benefits of using guidelines to conduct deprescribing. 
Based on the Bruyere Evidence-Based Deprescribing Guideline Symposium convened in March 
2018, the authors outlined the proceedings of the symposium (Conklin et al., 2019). In addition 
to articulating the barriers and facilitators identified by participants, they described ideas for 
future implementation that address the attitudes, concerns, and benefits of using guidelines to 
inform the practice of deprescribing medications (Conklin et al., 2019). 
Garfinkel, Ilhan, and Bahat (2015) wrote a lengthy expert opinion paper on the benefits 
of reducing medication for the oldest, most frail patients with limited life expectancy. They used 
research to support their passionate call for providers to systematically review and reduce 
medications for this vulnerable population (Garfinkel et al., 2015). They concluded that more 
research is needed to develop appropriate deprescribing tools for patients nearing the end of life 
(Garfinkel et al., 2015).  
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McGrath, Hajjar, Kumar, Hwang, and Salzman (2017) used case studies and a 4-step 
process to encourage deprescribing as a means for the reduction of polypharmacy. The authors 
identified practice goals, including avoidance of inappropriate medications for elderly patients to 
reduce ADEs, discontinuation of drugs whose risk ratio outweighs the benefits, and utilizing 
Beers and STOPP/START criteria as guidelines for deprescribing (McGrath et al., 2017). The 
authors assert that a reduction of polypharmacy improves the quality of life and requires patient 
participation for success (McGrath et al., 2017).  
The International Group for Reducing Inappropriate Medication Use & Polypharmacy 
(IGRIMUP) published a position paper with recommendations for the reduction of 
polypharmacy in July 2018 (Mangin et al., 2018). The group identified polypharmacy as an 
urgent health care issue and calls upon a global effort to make fundamental changes to health 
care systems to provide better care to patients with complex illness and multiple comorbidities 
(Mangin et al., 2018). Although the Beers criteria and STOPP/START tools are not validated, 
the peer group endorsed the use of these computerized tools to aid with systematic deprescribing 
(Mangin et al., 2018). Mangin and colleagues (2018) concluded that a patient-centered approach 
is the most effective way to achieve a reduction in inappropriate medication use and 
polypharmacy (IMUP), which they term an “epidemic of iatrogenic morbidity and mortality” (p. 
583).  
Finally, the emphasis on safe medication prescribing practices extends beyond the 
borders of our state, or even our nation. The World Health Organization (WHO) (n.d.) has issued 
a patient safety challenge to address avoidable medication errors and mitigate the risk of ADEs 
for people around the world. Known as Medication without Harm, the WHO campaign calls for 
healthcare professionals around the world to take actions that will reduce the risk of harm from 
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medication errors and promote safe prescribing and consumption of appropriate medications for 
all citizens, regardless of their place of residence (WHO, n.d.). Embedded in this challenge is a 
strategic framework for addressing polypharmacy as one of the three key action areas (WHO, 
n.d.). The goal of this challenge is to reduce the harmful effects of avoidable medication errors 
and ADEs by 50% in the next five years (WHO, n.d.). 
Limitations of Literature Review Process  
Useful tools to assist primary providers with reducing inappropriate, unnecessary, or 
harmful medications for patients at the end of life are just beginning to emerge in the literature. 
Multiple disciplines have contributed to the body of knowledge regarding the benefits of 
deprescribing for patients nearing the end of life, including nursing, medicine, and 
pharmacology. Still, there remains a lack of consensus on the appropriate methods to address 
polypharmacy in the frail, elderly residents of LTC (Palagyi et al., 2016). There is a need for 
guidelines to assist with the complex decision-making required to deprescribe medications for 
patients with multiple comorbidities who are nearing the end of life (Curtin, Dukelow, et al., 
2019; Thompson et al., 2019).  
Until recently, tools for deprescribing focused on the reduction of medications for a 
single disease process rather than complex, multimorbid conditions. Criteria developed for a 
comprehensive medication review, including the Beers and STOPPFrail criteria, have not been 
validated using randomized controlled trials (RCTs) (Thompson et al., 2019). Thus far, no one 
has published a longitudinal study demonstrating the long-term effectiveness of deprescribing on 
patient outcomes (Farrell, Pottie, et al., 2016). Few studies quantify the financial benefit of 
deprescribing for the patient and facilities. Still, the cost-benefit of preventing one ADEs and the 
avoidance of physical and emotional pain for the patient contribute to the overall advantage of 
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systematic deprescribing. Finally, many of the studies included in this literature review were 
conducted internationally without validation regarding the applicability of the results to the 
United States health care system.  
Discussion  
Conclusion of findings. Patients under the care of hospice services who reside in LTC 
facilities are vulnerable to polypharmacy, typically defined as taking five or more medications 
(Jokanovic et al., 2015). Polypharmacy correlates with a reduced quality of life for these patients, 
increased morbidity related to adverse drug events (ADEs), decreased functional status, 
increased hospitalization, and premature death (Jokanovic et al., 2015). Deprescribing is a 
systematic method used to identify and eliminate unnecessary, inappropriate, or harmful 
medications to improve patient outcomes (Page et al., 2016). Although research on deprescribing 
for complex, multimorbid patients at the end of life is still emerging, there is a substantial body 
of evidence that deprescribing does not cause harm and leads to risk reduction and improved 
functioning for patients residing in LTC (Kua et al., 2019). Providers and staff must take the time 
to engage patients and their family members to educate them on the risks and benefits of 
cessation of individual medications and obtain consensus for medication reduction from patients 
and their surrogate decision-makers (Dees et al., 2018).  
The goal of this DNP project was to share with facility providers and pharmacists the 
most current body of knowledge regarding appropriate medication deprescribing for patients 
under hospice care who reside in LTC. These providers hold prescriptive authority over hospice 
patients who live in their facility, and the pharmacist performs regular medication reviews, 
making them integral to the task of deprescribing. The project fostered collaboration between the 
participating agencies and bolstered support for adopting a systematic method of medication 
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reduction based on the latest studies and guidelines. Through promoting of interagency and 
interprofessional collaboration, this DNP project provided support for the systematic review of 
medications for all hospice patients residing in LTC, improved quality of life for the patients, 
increased regulatory compliance for the facility, and reduced costs related to polypharmacy for 
both agencies.   
Advantages and disadvantages of findings.  The benefits to the reduction of 
polypharmacy for LTC residents nearing the end of life are abundant in the literature. Studies 
show that deprescribing unnecessary and inappropriate medications lead to the mitigation of 
risks related to ADEs and improved quality of life (Kua et al., 2019).  Elimination of 
unnecessary medicines reduces falls, improves cognition, improves overall functioning, and 
promotes a sense of well-being for the patient (McNeil et al., 2016; Schenker et al., 2019). Other 
advantages include decreased costs for the LTC facility, as their staff will be responsible for 
dispensing fewer medications. Studies support a reduction in ADEs related to deprescribing of 
inappropriate or unnecessary medications, which will save money and increase compliance with 
regulatory mandates (Garfinkel et al., 2015).  
For the hospice agency, deprescribing reduces the overall cost of medications that the 
agency provides for the patient in collaboration with the LTC facility’s pharmacy vendor. There 
is also an incentive to reduce the total number of drugs used by hospice patients to meet the 
hospice agency’s targeted goal for reduction of medications per capita and create leverage for 
overall cost reductions with the hospice contracted pharmacy provider. Equally as important, 
there is an opportunity to develop interagency and interprofessional collaboration and strengthen 
community partnerships.  
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The disadvantage to this chosen intervention is the possibility that providers will not see 
the benefit in attending the educational session, or that they may be resistant to changing their 
prescriptive practices. The providers and pharmacist at the LTC facility are very busy 
professionals whose time is valuable. The author’s challenge was to convey the importance of 
this intervention to facility providers and to engage the physician, nurse practitioner, and 
pharmacist so that they embraced the value of deprescribing and chose to incorporate this new 
task in their daily routine. The measure of success for this project was a reduction in the number 
of inappropriate, unnecessary, or harmful medications prescribed to each hospice patient residing 
in the LTC facility.  
Utilization of findings in practice change. There is a growing body of literature that 
supports the concept of deprescribing for patients under hospice care who reside in LTC 
facilities. The benefits of reducing polypharmacy and eliminating unnecessary and inappropriate 
medications are improved quality of life, reduced adverse drug-related events, and improved 
mobility and functioning (Garfinkel et al., 2015). The planned intervention was an educational 
session for the facility physician, nurse practitioner, and pharmacist regarding deprescribing for 
hospice patients residing in LTC. The author conducted an educational session at the LTC 
facility site in southwestern NC. The author and LTC project lead/administrator collaborated to 
choose a date for the project intervention based on the availability of the providers and the 
pharmacist.  
A pre- and post-session survey to collect project-specific data from participants, 
including the likelihood that the participant will deprescribe medications for hospice patients 
under their prescriptive authority as a result of the educational session, was included in the 
project plan. The survey explored the willingness of participants to deprescribe specific 
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categories of medications that may be harmful, inappropriate, or unnecessary for hospice 
patients. A reference guide containing resources, including tools and guidelines for effective 
deprescribing, was provided to each participant at the end of the educational session.  
Throughout the project implementation phase, the author made regular visits to the 
facility to provide support and foster communication between the collaborating agencies, until 
the world-wide pandemic, COVID-19, impacted the project. After the LTC facility implemented 
restrictions to visitation due to COVID-19, the project author contacted the participants via 
online platforms, conference calls, electronic mail, and cell phone texts. The project author 
collected data on the number and type of medications prescribed before and after the intervention 
using the hospice electronic medical record (EMR). Once data was analyzed, the author 
presented the results to project participants at both participating agencies via online meeting 
platforms, including Microsoft Teams and Zoom.  
Summary  
Patient satisfaction and quality of life are the main emphases of this quality improvement 
(QI) project; however, containment of healthcare costs is an essential consideration. A reduction 
in the number of unnecessary and inappropriate medications taken by patients nearing the end of 
life who reside in LTC reduces falls, improves cognition, and improves functionality. Each fall 
prevented, or hospitalization avoided as a result of reduced polypharmacy yields cost savings for 
the facility and hospice organization. There is also the benefit of reduced human suffering for the 
patient. Additional considerations include savings on labor when facility staff dispense fewer 
medications and a reduction in the gross cost of medicines for hospice.  
The IHI Triple Aim seeks to improve the health of a specific population and the 
population in general, reduce healthcare costs, and improve satisfaction for individuals who are 
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consumers of healthcare (IHI, 2019b). This DNP project meets each arm of the Triple Aim by 
reducing the number of unnecessary medications taken by hospice patients who reside in LTC. 
Medication reduction improves the quality of life, reduces the risk for adverse drug events, and 
reducing health care costs through the elimination of unnecessary medication costs and avoiding 
expenses related to ADEs. The reduction of unnecessary medications in older adults with 
disabilities is one of the Healthy People 2020 measures (HHS, 2019). One goal of Healthy 
People 2020 is a 10% reduction in unnecessary medications in this patient population, which 
coincides with the anticipated outcomes for this DNP project.   
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Chapter Three:  Theory and Concept Model for Evidence-based Practice  
Deprescribing to reduce polypharmacy for patients nearing the end of life who reside in 
long-term care facilities requires careful consideration to minimize negative consequences. 
Effective communication regarding the risks and benefits of deprescribing must occur to reach a 
consensus among the prescriber and the patient or surrogate decision-maker and achieve an 
improved quality of life for the patient (Palagyi et al., 2016). Theoretical frameworks and 
evidence-based practice models form the foundation for effective communication to achieve 
lasting change. Everett M. Rogers (1995) developed a conceptual framework known as diffusion 
of innovations that uses the principles of behavioral science to guide effective change within 
organizations. Kurt Lewin is a psychologist whose evidence-based theory of planned change also 
guides the principles necessary to motivate individuals and organizations to undertake the effort 
needed to move from the status quo through change to create a new normal that is both positive 
and enduring (Oberleitner, 2019). 
Concept Analysis  
 The literature defines deprescribing as a systematic approach to medication reduction that 
eliminates unnecessary, harmful, or inappropriate medications to achieve improved patient 
outcomes (Page et al., 2016; Palagyi et al., 2016). The concept of deprescribing has emerged in 
response to the ever-increasing evidence of the adverse outcomes associated with polypharmacy 
(Paque, Elseviers, et al., 2019). Polypharmacy, the antecedent to deprescribing, is generally 
defined as taking five or more medications or taking any medication that is ineffective, 
inappropriate, or unnecessary (McGrath et al., 2017). Polypharmacy contributes to reduced 
quality of life and increased risk for ADEs, particularly for patients who are nearing the end of 
life (McNeil et al., 2016). 
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 Deprescribing has several key attributes that define the concept, including patient-
centered care, patient safety, perceived quality of life, and complexity of care. At the center of 
deprescribing is the idea of patient-centered care. Garfinkel et al. (2015) found that open 
communication with patients regarding the risk and benefits of ongoing medication use was at 
the core of effective deprescribing. This patient-centered approach, which embraces the 
individual’s goals of care, fosters shared decision-making and promotes the perception of 
improved quality of life among patients with a limited life expectancy who reside in long-term 
care (Palagyi et al., 2016). Multiple comorbidities and complex health issues lead to 
polypharmacy and a higher risk of ADEs in the selected patient population (Kua et al., 2019). As 
patients near the end of life, reducing polypharmacy that contributes to ADEs through systematic 
deprescribing enhances patient safety and improves the quality of life (Paque, Elseviers, et al., 
2019).   
 The attributes of deprescribing also define some of the challenges and barriers to 
achieving medication reduction, particularly for patients who reside in long-term care and are 
nearing the end of life. Paque, Vander Stichele, et al. (2019) identified barriers to deprescribing 
for this specific patient population on three levels, including organizational, professional, and 
patient/family-related barriers. Effective deprescribing for patients with complex health issues 
requires time and resources, embracing an interdisciplinary, patient-centered approach to 
evaluation and decision-making (Palagyi et al., 2016). Patients and surrogate decision-makers are 
often reluctant to stop medications prescribed by trusted providers and may view deprescribing 
as giving up hope. Current providers must devote time to effectively communicate the risks and 
benefits of deprescribing to promote patient safety and improved quality of life (Palagyi et al., 
2016).  
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 Empirical referents for the concept of deprescribing include an understanding of the 
individual patient’s goals of care, systematic medication reviews, effective communication 
among providers and patients, and a willingness to stop any unnecessary medications. Essential 
to the process of effective deprescribing is an interdisciplinary review of medication lists for 
each patient. The ideal team includes nursing staff, pharmacists, and providers (McGrath et al., 
2017). Communication between the provider and patient or surrogate decision-maker is essential 
to understanding the goals of care, patient preferences, and openness to deprescribing (Conklin et 
al., 2019). Shared decision-making is central to the concept of deprescribing and must include 
discussions of the risks and benefits of deprescribing specific medications to overcome barriers 
to medication reduction  
 Theoretical Framework  
 Naming the Theory. Everett M. Rogers’ (1995) theory, diffusion of innovations, 
provides the conceptual framework for this project. Rogers, a behavioral scientist, first published 
his theory on dissemination and infusion of innovative ideas into various social systems in 1962 
(Rogers, 1995). Through his ongoing work and an ever-increasing body of research by fellow 
behavioral scientists on innovation diffusion, Rogers has refined his theory to focus on 
communication as the catalyst for information exchange that leads to changes within various 
cultures. Known as the innovation-decision process, Rogers’ framework for his diffusion theory 
provides a five-step process that defines the movement from awareness of an idea to the 
incorporation that idea into the daily workings of an individual or organization (Rogers, 1995). 
 The five steps in the innovation-decision process of diffusion theory include knowledge 
or awareness of an innovative concept, persuasion which defines one’s attitude toward the new 
idea, and a decision regarding whether to embrace or reject the change (Rogers, 1995). Once the 
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new concept is accepted, the final two steps of the process, implementation and confirmation, 
begin, and the idea is incorporated and evaluated for ongoing use (Rogers, 1995). Rogers 
acknowledges that the movement from awareness to the incorporation of new ideas is a process 
over time, which he calls the innovation-decision period. The timeframe for incorporating new 
ideas, termed the rate of adoption, varies depending on the complexity of the issues and the 
culture of the organization. Organizations or individuals that favor the early adoption of new 
ideas demonstrate a rapid diffusion of innovative concepts. Those with a higher number of late 
adopters may require more time and effort to communicate the benefits of innovation and to 
convince decision-makers that the change is beneficial and that the new idea is worth adopting 
(Rogers, 1995) (see Appendix C).  
  Application to practice change. The five-step innovation-decision process that defines 
Rogers’ framework for the diffusion of ideas guided the development and implementation of this 
DNP project on deprescribing for hospice patients residing in LTC. The providers and 
pharmacists who participated in the educational session were familiar with the concept of 
deprescribing. The author’s task was to provide enough information during the intervention to 
compel the project participants to rethink their prescribing practices and focus on appropriate 
medication reduction for patients under hospice care. Effective communication was essential to 
leading these busy professionals through the steps necessary to view the commitment to review 
medications and systematically deprescribe as a valuable use of their time. Providing tools to 
streamline the implementation of the deprescribing process assisted in minimizing the time 
needed to perform this new task.  
 After the educational session, the facility pharmacist and hospice nurse practitioner 
conducted periodic medication reviews and communicated deprescribing recommendations to 
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the facility providers.  Next, the author collected data on the number of medications prescribed to 
hospice patients in the LTC facility, to assess the physician and nurse practitioner’s 
deprescribing practices and offer feedback and support regarding appropriate medication 
reduction. This process supported Roger’s steps of implementation and confirmation. The goal 
was to confirm the value of their decision to incorporate deprescribing into their routine.  
Barriers identified by the author were addressed in the second step of the process, using 
persuasion to convince providers to adopt the practice of deprescribing. Throughout this process, 
the DNP student addressed concerns that prevented project participants from moving forward 
with new prescribing practices. Frequent follow up allowed for ongoing communication to 
support those who were early adopters of the project and address the concerns of later adopters 
who require additional persuasion to embrace the value of deprescribing. This systematic 
approach to introducing change provided structure for the process and allowed for effective 
communication to optimize the opportunity for successful project outcomes.  
Evidence-Based Practice Change Theory  
Naming the Change Model. Change for many people creates uncertainty and 
disequilibrium, often meeting with resistance and skepticism, even among those who may benefit 
most. Kurt Lewin, a German psychologist, proposed a systematic method of planned change in 
1951 (Oberleitner, 2019). Lewin’s planned change theory suggests that impulsive or chaotic 
change breeds a sense of uncertainty, anxiety, and loss of control among workers, but that a 
systematic process can lead to improved functioning with minimal disruption (Oberleitner, 
2019). Lewin’s change model states that there must be a recognition of the need for change, 
momentum to push toward a new way of operating, and stabilization of the new process for 
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transition to be successful. He terms this three-step process unfreezing, movement, and 
refreezing (Oberleitner, 2019).  
Included in Lewin’s theory for successful change are the concepts of field and forces 
(Oberleitner, 2019). Fields are systems of any type, and Lewin notes that a change in one part of 
the system necessitates an assessment of the whole system to determine the overall effect of that 
change (Oberleitner, 2019).  Forces, as used in the theory of planned change, include both 
driving and restraining forces (Oberleitner, 2019). Oberleitner (2019) characterized driving 
forces as having strength, focus, and movement toward change. In contrast, restraining forces are 
anything or anyone that seeks to maintain the status quo and impede change (Oberleitner, 2019).  
In Lewin’s model, driving forces must overcome restraining obstacles to achieve the first 
step of unfreezing the status quo (Oberleitner, 2019). Movement occurs during the second phase, 
which is the adoption of the new process. The final step of refreezing occurs when a new 
equilibrium that includes the change is reached (Oberleitner, 2019). Lewin’s model 
acknowledges that emotions of discomfort, anxiety, and loss of control often accompany change 
and that a planned approach minimizes and overcomes emotional barriers to change (Oberleitner, 
2019). By assuming that there will be resistance to change, Lewin’s theory promotes the 
identification of system-specific obstacles to implementing new concepts, allowing change 
agents to address those issues as a part of the change process (Oberleitner, 2019). 
Application to practice change.  
Lewin’s planned change theory provided a useful model for this DNP project. First, the 
author identified the need for a change in prescribing practices for patients who reside in long-
term care and are nearing the end of life. It was imperative that prescribers and pharmacists who 
care for those patients also see the need to address the issue of polypharmacy. Once they agreed 
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with the need for change, unfreezing of current prescribing practices could occur. Next, there 
must be a movement toward change. The catalyst for this movement was the implementation of 
the project intervention, an educational session provided for the facility physician, nurse 
practitioner, and pharmacist on the body of research supporting deprescribing and the use of 
evidence-based tools to assist providers in appropriate deprescribing (see Appendix D).  
To effectively implement the desired change in prescribing practice, the author evaluated 
the steps of unfreezing, movement, and refreezing using the plan-do-study-act (PDSA) cycle 
(IHI, 2019a). PDSA provides a framework for quick evaluation of quality improvement efforts to 
identify the progress of the change, adjust the process to address barriers and gaps, and 
reevaluate for effectiveness in meeting the stated goal (see Appendix E). The PDSA cycle was 
used biweekly during the implementation period to evaluate the effectiveness of the educational 
session and subsequent medication reviews, as evidenced by a change in the number of 
inappropriate or unnecessary medications in seven specific medication categories prescribed to 
hospice patients in LTC.  
The plan in the PDSA cycle reflects an evaluation of the change, which, in this project, 
was a periodic review of data to determine the number and type of medications prescribed to 
each hospice patient residing in the LTC project facility. Do was the actual data mining that 
occurred six times during the project implementation phase. The author obtained data from each 
patient’s hospice electronic medical record (EHR) using the individual patient’s medication list 
found in the hospice EHR. The term study refers to the assessment of the findings based on the 
desired change (reduction of inappropriate, unnecessary, or harmful medications) and the 
development of further interventions to address shortfalls in the plan. The final step in the PDSA 
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cycle was to act with additional communication and education for the LTC pharmacist and 
providers to address identified barriers and unmet goals.   
Addressing barriers to change at regular intervals maximizes the opportunities for change 
(driving forces) and minimizes the resistance to altering prescribing practices (resisting forces). 
Finally, refreezing is confirmed using analysis of data regarding prescribing practices for hospice 
patients residing in long term care. The author reported data outcomes to the project participants 
and provided ongoing support for the maintenance of appropriate changes in prescribing 
practices. Lewin’s theory of planned change compliments Rogers’ theory of diffusion of 
innovation, and the PDSA cycle is a useful framework to assure the successful implementation 
of this DNP project and ultimately affect a positive outcome for patients.  
Summary  
 Change, while inevitable, can be challenging to initiate and often takes a catalyst to 
overcome barriers and resistance effectively. Even when a change is beneficial, as with 
deprescribing of unnecessary or harmful medications, there may be resistance. Using processes 
developed by multiple disciplines provides a foundation for effective change. Behavioral 
scientist Everett Rogers developed the theory of diffusion of innovations, which is the foundation 
for this DNP quality improvement project. Rogers’ theory provides a framework for effective 
change using a five-step process to move from awareness of innovation through a decision to 
adopt a new idea and ultimately implement and incorporate the change into the existing 
processes. Lewin, a psychologist, also studied methods of effective change and developed his 
three-step guideline for planned change, including unfreezing, movement, and refreezing. 
 The intervention for this DNP project was to educate the LTC facility providers and 
pharmacists regarding the benefits of deprescribing for patients who are nearing the end of life 
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while residing in LTC. The goal of the project intervention was to promote a change in 
prescribing practices that resulted in a reduction of unnecessary, inappropriate, or harmful 
medications for this patient population. The term deprescribing refers to a systematic review of 
medications to eliminate any drugs that are no longer appropriate, useful, or desirable. The 
antecedent to deprescribing, polypharmacy, is defined as taking five or more medications. The 
benefits of deprescribing are many, but the goal of improved safety and quality of life for 
hospice patients who reside in LTC is the desired outcome. Rogers’ theoretical framework and 
Lewin’s evidence-based guidelines for planned change, together with the PDSA cycle as a tool 
for evaluation of the effectiveness of the interventions, assisted project participants with 
decision-making for appropriate deprescribing in this unique patient population.   
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Chapter Four:  Pre-implementation Plan 
Successful outcomes for any project are dependent upon thorough planning, and this 
DNP project was no exception. Planning for implementation of the DNP project included five 
major areas beginning with clear identification of the project purpose. Next, project management 
encompassed assessing for organizational readiness for change and identification of team 
members, along with their expected contributions to the success of the project. Additional 
elements of pre-implementation planning included risk management, clarifying the process used 
to obtain organizational approval to conduct the project at the chosen site, and identifying the 
role of information technology in the project. A cost-benefit analysis was the third area of the 
project management, followed by the implementation of the process required to obtain 
Institutional Review Board (IRB) approval. The fifth and final category for the pre-
implementation plan was the evaluation process, including the determination of demographic and 
project-specific data to be collected during the project and the desired outcomes. Discussion of 
the evaluation tools, data analysis, and data management completed the pre-implementation 
planning phase.  
Project Purpose 
 The purpose of this DNP project was to provide education regarding the benefits of 
deprescribing unnecessary, inappropriate, and harmful medications for hospice patients residing 
in LTC to the providers and pharmacists employed at the project facility. The educational session 
presented current research supporting deprescribing and offered tools that could be used by the 
pharmacist and providers to streamline the process of decision-making for deprescribing. The 
effectiveness of the project was evaluated by analyzing data on both the number and class of 
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medications discontinued for hospice patients who reside in the LTC facility during the 
implementation timeline.  
Project Management 
Organizational readiness for change. The hospice organization with whom patients are 
enrolled has the responsibility to provide optimal care to those patients regardless of their place 
of residence. The development of this DNP project occurred in response to challenges 
encountered by the author in reducing inappropriate and unnecessary medications for hospice 
patients residing in LTC. The hospice organization and their contracted pharmacy vendor were 
enthusiastic about the project, which has the potential to reduce costs associated with 
unnecessary medications as well as improve the quality of life for patients under their care. For 
the hospice organization, there were no barriers related to the project, and members of the 
organization were ready for the anticipated change resulting from the planned collaborative 
session. The administrator of the LTC facility, where the hospice patients reside, immediately 
gave her unqualified support for the project. The initial barrier identified was that the providers 
and pharmacists were unaware of the project, and their willingness to participate was unknown. 
Before the implementation of the educational session, the facility administrator/project lead 
contacted each participant to discuss the planned educational meeting and begin building 
anticipation of the project implementation. 
Interprofessional collaboration. Included in the project team were the facility physician 
and nurse practitioner. They were vital members, as they are the ones with prescriptive authority 
over the hospice patients who reside in the LTC facility. Ultimately, they were the decision-
makers and, as such, were responsible for writing orders for discontinuation of medications that 
were deemed inappropriate, unnecessary, or harmful to the target patient population. The 
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pharmacist, who conducts monthly medication reviews for all patients who reside in the facility, 
was another key member of the project. The pharmacist assisted in identifying potentially 
inappropriate medications for the hospice patients living in the facility and recommended 
discontinuation of target medications to the providers. This collaboration streamlined the 
deprescribing process and increased the likelihood that the providers would have the time and 
motivation to deprescribe as appropriate.  
Risk management assessment. The ability to manage the inherent risks associated with 
the project were analyzed using the strength, weakness, opportunities, and threats (SWOT) 
model (see Appendix F). One internal strength of the project was the author’s experience and 
expertise in managing medications for hospice patients. The author earned certification as an 
advanced certified hospice and palliative nurse (ACHPN) and has five years’ experience 
managing medications for patients nearing the end of life. An additional strength was the 
growing body of evidence supporting the discontinuation of inappropriate, harmful, or 
unnecessary drugs for hospice patients, particularly those who reside in LTC. The availability of 
tools, both electronic and written, that assist in decision-making for deprescribing medications 
for patients with complex illness at the end of life was another strength of this project. These 
tools provide a framework for decision-making so that the deprescribing process is as efficient 
and manageable as possible for busy providers. Accessibility and availability of data to assess 
the outcomes was another strength of the project.  
Weaknesses include the limited time for implementation and data analysis, limitations of 
available research on deprescribing for patients with multiple comorbidities and complex illness, 
and the time-consuming nature of the deprescribing process. The implementation of the initial 
collaborative educational session was a one-time event; however, the process for incorporating 
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deprescribing into daily practice took several months to solidify. Data collected at regular 
intervals during the implementation of the project did not fully reflect the change process and 
outcomes. Unfortunately, most tools created to assist with deprescribing decision-making focus 
on a single disease model. They do not reflect the complexity of the health status for most LTC 
patients nearing the end of life. Finally, deprescribing adds another time-consuming task to the 
practice of busy providers. Finding ways to streamline the process was essential to influencing 
providers to incorporate this critical task into their daily practice.  
External factors that influenced the project included both opportunities and threats. 
Opportunities included the financial benefits for the LTC facility when there are fewer 
medications to dispense, thus eliminating unnecessary tasks and reducing costs of care. The 
inclusion of the facility pharmacist provided an opportunity for increasing the chance of success 
of the project, as she assisted in identifying medications for potential deprescribing, making the 
process more efficient for the providers. There was a benefit of improved patient satisfaction, 
which reflects well on both the hospice organization and the LTC facility in which the hospice 
patient resides. Reduced pharmacy costs for individual hospice patients and the potential for 
reduction of pharmacy contractual costs for the hospice organization were an added benefit of 
this project. Finally, and most importantly, was the reduction of potential ADEs and improved 
quality of life for hospice patients residing in LTC. 
Threats to the project included the willingness of providers to incorporate an additional 
task, deprescribing, into their busy practice. The physician and nurse practitioner employed by 
the LTC facility were under no obligation to embrace the practice of deprescribing. This process 
can be time-consuming, and providers may be reluctant to take on additional responsibilities that 
will contribute to their already heavy workload. The collaborative educational session with 
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providers and the pharmacist employed by the LTC facility was central to the success of the 
project. Additional threats included securing permission to conduct the project educational 
session at the LTC facility, which required the facility administrator to be named as project lead 
and complete a QI module before submitting a request for the LTC facility’s internal IRB 
approval.  
Organizational approval process. The author developed the DNP project in response to 
the issue of polypharmacy encountered in the course of her work as a hospice nurse practitioner. 
The data regarding the average number of medications prescribed to each patient in the author’s 
hospice organization was well above the national average for similar organizations serviced by 
their contracted pharmacy provider. In discussing this data with an executive leader of the 
organization, it became clear that the population of hospice patients residing in LTC was the only 
group for whom hospice providers did not influence prescriptive practices. Together, the 
executive leader and the author developed a plan for addressing this deficit and presented it 
jointly to the Chief Executive Officer (CEO) of the hospice organization. The project proposal 
included a cost-benefit analysis as well as data that supported improved quality of life for 
hospice patients residing in LTC when unnecessary, inappropriate, and harmful medications are 
deprescribed. The CEO agreed to be the project champion and gave final approval for 
conducting the project through the hospice organization (see Appendix G). 
Information technology. Technology has become an integral part of healthcare and is 
essential to providing optimal care, retaining documentation of that care, and analyzing the 
effectiveness of the care provided to patients. This project utilized several technologies for the 
development and analysis of outcomes, including NetSmart© EHR (Netsmart Technologies, 
Inc., 2019). Excel provided an effective platform to organize and analyze data and develop 
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meaningful graphics to visualize outcome results. PowerPoint was employed to create an 
educational presentation for the pharmacist and providers participating in the educational 
intervention for the project. The author recommended the use of an electronic application called 
MedStopper® (n.d.) to assist providers with the deprescribing decision-making process. 
MedStopper® (n.d.) is a non-validated, web-based tool developed through expert opinion that 
helps providers with decision-making regarding medication deprescribing.  
Cost Analysis of Materials Needed for Project 
 The cost of the collaborative educational session was minimal. It included a bound 
handout and light snack for all participants at the meeting, and mileage to the hospice facility and 
LTC facility totaling just over $300 (see Appendix H). Financial benefits were quantifiable in 
terms of the potential cost savings for avoidance of ADEs related to polypharmacy and 
inappropriate prescribing. Avoidance of one fall provides significant cost-benefit for both the 
hospice and LTC organizations. Burns, Stevens, and Lee (2016) estimate the average cost of a 
non-fatal fall for an older adult in 2016 was $9,463. These costs increase with age and with 
complications such as hospitalization (Burns et al., 2016).  
Reduction in unnecessary medications results in lower costs for the hospice organization 
and offers supportive data for renegotiation of contracted per diem pharmacy costs with the 
hospice pharmacy vendor. Cost savings for the LTC include a reduction of the workload for the 
bedside nurse who administers medications to the hospice patient, as well as avoidance of missed 
revenue days when the LTC facility must send residents to the hospital for evaluation and 
treatment of ADEs. Most importantly, there is an unquantifiable saving in the pain and suffering 
experienced by patients who suffer ADEs due to inappropriate, unnecessary, or harmful 
medications. The avoidance of just one fall more than accounts for the cost of the DNP project. 
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Plans for Institutional Review Board Approval 
 The author submitted details of the DNP project and obtained a waiver from East 
Carolina University (ECU) Institutional Review Board (IRB) based on the quality improvement 
structure of the project. The IRB issued the exemption after the author submitted ECU’s quality 
improvement/program evaluation self-certification tool. The author gave a brief description of 
the project and answered eight yes/no questions about the structure and purpose of the project. 
The author then submitted the self-certification tool to the ECU IRB link provided by project 
faculty and received notification immediately that the IRB granted a waiver.  
The hospice organization did not have an IRB board or other formal process for project 
approval. The CEO of the hospice organization granted permission for the project following an 
informal presentation. The benefits of the project reviewed during this meeting included 
reduction of overall pharmacy costs, improved patient satisfaction, and decreased risk of ADEs, 
resulting in further cost savings for both hospice and the LTC facility. The parent company of 
the LTC facility site for this QI project had an internal IRB board. The facility’s organizational 
IRB required the site champion to complete a QI educational module and electronically submit a 
summary of the project and data collection tools developed by the author to the review board. 
The documents were provided by the LTC site champion/project lead to that organization’s IRB, 
and the project was determined to be a QI project with an IRB waiver granted. 
Plan for Project Evaluation 
Demographics. The target audience for the educational sessions were facility providers, 
including the physician and nurse practitioner, and the facility pharmacist. The LTC IRB 
required the author to remove demographic questions from the project data collection tool to 
comply with the LTC IRB definition of quality improvement versus research. Project-specific 
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data was collected to assess each participant’s willingness to deprescribe medications for hospice 
patients under their care based on the information provided during the educational session (see 
Appendix I & Appendix J).  
A variety of methods were employed to report data, depending on the question structure. 
Responses from each participant regarding the ideal number of prescribed medications and their 
willingness to deprescribe medications for hospice patients was compared before and after the 
educational presentation and reported as aggregate data and percentages. Comparative data for 
each participant’s willingness to deprescribe specific categories of medications before and after 
the educational session was analyzed and reported using percentages. The author used a variety 
of formats, including bar graphs, pie charts, and line charts to demonstrate outcomes visually.  
Outcome measurement. The desired outcome for the DNP project was a reduction of 
unnecessary, inappropriate, or harmful medications prescribed to hospice patients residing in the 
LTC facility. The author compared baseline data obtained from the hospice EHR at the start of 
the project to data collected intermittently and after the project implementation.  The data 
included the number of medications prescribed in seven target categories to each hospice patient 
living at the project facility. Data were collected every two to three weeks to assess the progress 
of the deprescribing efforts and to address barriers to deprescribing with the facility pharmacist 
and providers. The author presented intermittent data monthly to project participants to offer 
feedback on deprescribing efforts and encourage ongoing incorporation of deprescribing 
practices. Success for the project outcome was defined as deprescribing at least one inappropriate 
medication, with an overall goal of a 10% reduction of unnecessary medications for the target 
patient population. Measurement of process outcomes was evaluated based on the ongoing use of 
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deprescribing methods by the facility providers for patients admitted to hospice services after the 
start of the DNP project.  
Evaluation tool. The author developed an excel spreadsheet for organizing and analyzing 
data collected from the hospice EHR and hospice pharmacy provider. The author compared data 
in the spreadsheet to measure the effectiveness of the project intervention. By comparing the 
number of overall medications prescribed to each patient at the beginning and completion of the 
project, as well as at regular intervals throughout the project implementation, the author 
demonstrated the effectiveness of the project intervention. The number of medications prescribed 
to each patient in specific categories, including vitamins and supplements, statins and 
cholesterol-lowering medications, anticoagulants, cognitive-enhancing medications, 
antihypertensives, and diabetic medications, were recorded on each of the data collection dates. 
These categories reflected possible inappropriate, unnecessary, or harmful drugs prescribed to 
hospice patients and were compared at the start of the project implementation and monthly until 
the project conclusion (see Appendix J).   
Data analysis. Using an Excel spreadsheet, the author tabulated and analyzed the results 
from the pre- and post-educational session data collection tool completed by the participants. 
Visual representations of the data collected from the project data collection tool were created in 
Excel, including pie charts and run charts. Outcome data were collected at the start of the project 
and then every two to three weeks. The author shared intermittent outcomes data at regular 
intervals with the facility providers and the pharmacist. Data were reported to both the hospice 
site champion and LTC facility administrator/project lead at the end of each month during the 
implementation period. Each data set was compared to prior reports and assessed for trends in 
the reduction of target medication categories and the overall number of medications.  
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There are no specific national, state, or local benchmarks for the ideal number of 
medications prescribed to hospice patients residing in LTC. Consequently, the project was 
deemed successful by the reduction of a single unnecessary, inappropriate, or harmful 
medication. The overall outcome goal of the project was a 10% reduction in the number of drugs 
prescribed to this patient population, which aligns with the goals of Healthy People 2020 (HHS, 
2019).  
Data management. The author completed coding of the DNP data collection, which was 
verified by a hospice colleague who was also a DNP student at ECU. Data collected during the 
DNP project remained deidentified and secure on the hospice server and the author’s password-
protected laptop. Hard copies of the survey tools and data collection spreadsheets provided back 
up in case of electronic failure. Surveys were uploaded electronically for storage, and hard copies 
kept secured in the author’s locked office at hospice. The author shared data with the LTC 
facility and the hospice organization after the project implementation ended. Data will be kept 
for five years after project completion, after which electronic data will be erased, except for a 
single thumb drive, and hard copies will be shredded/destroyed.  
Summary 
 The DNP project pre-implementation planning included articulating the project purpose, 
organizing steps of project management, analysis of costs and benefits of the project, planning 
for IRB approval, and planning for project evaluation after implementation. This DNP project 
focused on deprescribing inappropriate, unnecessary, or harmful medications for hospice patients 
who reside in LTC facilities. Each of the organizations involved in the project, hospice and the 
LTC facility, verbalized enthusiastic support of the project goals and intended outcomes. The 
author selected appropriate members of the interprofessional team and used a SWOT analysis to 
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identify strengths, weaknesses, opportunities, and threats to completion of the project. The author 
then outlined the necessary steps taken to gain IRB approval through both ECU and the LTC 
organization and completed a cost-benefit analysis. Next, the author discussed the plan for 
demographic and project-specific data collection and reporting and identified outcome measures. 
Finally, methods for data analysis and strategies for data management were clarified.   
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Chapter Five:  Implementation Process 
The foundation of this quality improvement project was careful planning leading up to 
the implementation phase. Implementation of this DNP project began with an educational 
session provided for the pharmacist and providers employed by the LTC facility. During this 
collaborative meeting, the DNP student informed participants about the growing body of 
research supporting deprescribing for hospice patients residing in LTC and introduced evidence-
based guidelines available to assist with deprescribing decisions. The effectiveness of the 
educational intervention was evaluated based on data obtained from the hospice EHR and 
pharmacy vendor reports. The author analyzed data at regular intervals for the number of 
medications prescribed in the seven target drug categories to hospice patients living in LTC. 
Using the PDSA model and the data analysis, the author engaged project participants in ongoing 
discussions regarding appropriate deprescribing and incorporating this process into their daily 
practice.  
Setting 
        The DNP project implementation involved two sites, including a for-profit LTC facility in 
NC owned by a large healthcare organization and an independent, non-profit, community-based 
hospice. The hospice organization has been a long-time community partner with the LTC to 
provide specialized care for patients with a prognosis of six months or less. Hospice patients who 
reside in LTC are the responsibility of the hospice agency but remain under the prescriptive 
authority of the facility providers. A hospice team is assigned to the patient and works 
collaboratively with LTC facility staff to provide care for their mutual patients.  
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Participants 
        The DNP project participants included a pharmacist, physician, and nurse practitioner, all of 
whom are employed by the LTC in which hospice patients reside. Also included was the facility 
pharmacist’s supervisor, who is a PharmD. Although the target population is under the care of 
hospice, the prescriptive authority for these patients remains with the facility providers due to 
their place of residence. Project participants were included based on their role in evaluating 
medications and their ability to prescribe and deprescribe medications for patients in the LTC 
facility. The facility administrator was the project lead, assisting in coordinating the educational 
session and acting as a liaison between the author and project participants.   
        Additional participants included the CEO for the hospice organization, who was the site 
champion. The CEO provided project approval for the hospice organization and ongoing support 
of the project. The author worked collaboratively with a DNP leadership student whose doctoral 
QI project was parallel and complementary to this project. The colleague provided education 
regarding deprescribing for hospice patients in LTC to nurses employed by the same LTC 
facility. Offering training to both providers and nursing staff during the same implementation 
period allowed the author and her DNP student colleague to create an integrated and 
collaborative focus on deprescribing, maximizing the potential for successful outcomes.          
Recruitment 
        Initial recruitment began when the author met with the LTC facility administrator to outline 
the project and obtain support and approval for using the facility as the DNP project site. The 
administrator received a brief written outline of the project, including a review of the benefits to 
both the facility and patients. There was a focus on partnership and collaboration between the 
hospice organization and the LTC facility, which would provide mutual benefits in cost savings, 
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reduction of ADEs, and, most importantly, provide for an improved quality of life for the hospice 
patient. The facility administrator was supportive of the project goals and embraced the vision 
for an educational session to share evidence-based guidelines with the facility providers and 
pharmacists.  
Due to organizational requirements, the facility administrator was named as the project 
lead and completed a QI educational module provided by her employer. The administrator 
submitted a summary of the project, which the author provided, to the organization’s internal 
IRB to determine the nature of the project- quality improvement versus research- and to obtain a 
waiver. Once the project lead received IRB approval for the project site from her organization, 
further plans for recruitment of the providers and pharmacists were made in collaboration with 
the facility administrator.  
The project participants were chosen based on a convenience sample due to their role 
within the organization. The facility administrator was instrumental in offering insights regarding 
possible barriers to engaging the participants, particularly for the physician whom she described 
as “old school.” The project lead characterized the nurse practitioner and pharmacist as being 
“open” and likely to be supportive of the goal of deprescribing medications no longer appropriate 
for patients nearing the end of life. Participants were concerned about incorporating extra work 
or a time-consuming process into their already busy practice.  
Implementation Process  
        The project implementation phase began on day 1 in mid-January 2020 with a meeting 
between the author and hospice site champion to discuss the initial phase of implementation and 
data collection. Next, the author met with the LTC administrator to confirm provider and 
pharmacist schedules and determine an appropriate date for the collaborative educational session. 
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The author completed the first data collection using the hospice EMR before the educational 
session. Data included the number of medications prescribed to each hospice patient in the seven 
specific drug categories.  During the first week of the DNP project implementation, the project 
lead contacted each project participant to confirm the date and time for the educational session. 
The author scheduled a single educational meeting for the project participants to minimize 
disruption to their workflow, maximize the opportunity to promote change in their prescribing 
practice for hospice patients and begin building a foundation for a trusting, collaborative 
partnership. The educational session took place within the first two weeks of project 
implementation. 
        After the educational session, the hospice nurse, facility pharmacist, and hospice nurse 
practitioner/DNP student met every two to three weeks to conduct medication reviews for each 
hospice patient. Data on the number and categories of medications prescribed to hospice patients 
residing in the project site LTC facility were collected and analyzed every two to three weeks 
with aggregate data shared with participants at the end of each month during the implementation 
phase. Using the PDSA model, the effectiveness of the educational sessions was evaluated based 
on the changes seen in the number and types of medications prescribed for the hospice patients 
residing in the project LTC facility. Barriers were identified and addressed at informal biweekly 
meetings with each provider and monthly with the pharmacist. Meetings were held monthly with 
the project lead/LTC facility administrator and the hospice organization site champion to discuss 
strategies for overcoming barriers identified and share incremental outcomes for the first month 
after implementation. Subsequent meetings with LTC staff were deferred or conducted virtually 
due to visitation restrictions enacted in response to the global pandemic, COVID-19. The cycle 
of data collection, feedback provided to the site champion and facility administrator, and 
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informal meetings with project participants to discuss successes and ongoing opportunities for 
additional deprescribing continued throughout the implementation period, with adjustments 
made to incorporate virtual platforms.   
Plan Variation 
        Using the PDSA model, the author adjusted the project plan throughout the implementation 
phase based on barriers revealed in the analysis of periodic outcomes data.  Regular 
communication with the physician, nurse practitioner, and pharmacist provided opportunities to 
discuss perceived and real challenges to implementation. Once periodic data was analyzed, 
successes were shared to reinforce appropriate deprescribing practices. The author intermittently 
reviewed deprescribing tools to assist participants with the deprescribing process. The facility 
pharmacist, hospice nurse, and DNP project author comprised the interdisciplinary team that met 
regularly every two to three weeks to review all medications for hospice patients residing in the 
LTC facility. The team reviewed medications for patients admitted to hospice after the initial 
implementation date at the next regularly scheduled medication review meeting. Based on the 
results of the PDSA process, the author facilitated discussions between the pharmacist and 
providers to identify the most effective means for communicating recommendations for 
deprescribing. Providers shared their preferences for receiving staff recommendations for 
deprescribing, which were integrated into the process as well. 
 The global pandemic, COVID-19, impacted this project. The project implementation 
occurred before the development of social restrictions and limited access to LTC facilities. Once 
those restrictions began, communication continued using telephone conferences, virtual meeting 
platforms like WebEx and Zoom, electronic mail correspondence, and cell phone texts. The 
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project author collected outcomes data using the hospice EHR from a remote location using the 
hospice virtual private network (VPN).  
Summary 
        The planned implementation of the DNP project included an educational session with 
facility providers and the pharmacist to share evidence-based research on the benefits of 
deprescribing unnecessary and inappropriate medications for hospice patients residing in their 
facility. The author collected the initial data on medications prescribed in seven specific 
medication categories to this patient population before the implementation of the education 
session. After the educational intervention, data was collected regularly every two to three weeks 
until the conclusion of the implementation period. Informal periodic meetings were held with the 
providers and the pharmacist to discuss successful deprescribing practices and to address barriers 
to appropriate deprescribing for hospice patients residing in the LTC facility. The author met 
with the LTC facility administrator/project lead and the hospice site champion periodically 
during the implementation phase to discuss any barriers identified and to disseminate intermittent 
results of the PDSA cycle and project outcomes.  Aggregate reporting of data to both the hospice 
site champion and project lead/facility administrator occurred at the end of each month during 
the implementation phase. After the implementation of social and organizational restrictions due 
to COVID-19, project participants continued to communicate using telephone conferences, 
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Chapter Six:  Evaluation of the Practice Change Initiative 
The effectiveness of a quality improvement project is measured by the degree to which it 
achieves its goals and desired outcomes. The objectives of this DNP project were three-fold: 
first, to educate providers and pharmacists regarding the growing body of evidence supporting 
the elimination of unnecessary, inappropriate, and harmful medications for patients who reside in 
LTC and are under hospice care. The second goal was to appreciate an actual reduction in the 
number of medicines prescribed to this patient population in seven specific medication categories 
shown to be inappropriate or harmful for patients nearing the end of life. The third goal was to 
improve the quality of life of hospice patients residing in LTC through the reduction of pill 
burden and avoidance of ADEs related to polypharmacy. Also, deprescribing unnecessary 
medications yields costs savings for both the LTC facility and hospice organization through the 
avoidance of ADEs that lead to hospitalizations and increased healthcare costs and the reduction 
of labor and supply costs related to fewer prescribed medications.  
Participant Demographics 
           Project participants included a physician, a nurse practitioner, and two pharmacists, one of 
whom was assigned to the LTC facility, and the other was a supervisor. Project participants were 
employees of the LTC facility in which patients of the hospice organization reside. The facility 
administrator and project lead recruited participants, in collaboration with the DNP student, 
based on their role of provider and pharmacist. Although it was a small group in numbers, these 
critical members of the DNP project were responsible for making medication recommendations 
as well as prescribing and discontinuing medications for the targeted patient population. The 
original DNP project data collection tool contained demographic questions, but the DNP student 
removed those questions at the request of the facility’s IRB. The physician is an MD, and the 
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nurse practitioner and pharmacists hold doctoral degrees in their respective disciplines. There 
were one male and three female participants who attended the project intervention/ educational 
presentation.   
 The two participating agencies for this DNP project included an independent, nonprofit 
hospice that serves patients at the end of life and a corporate-owned long-term care facility. The 
hospice agency has just over one hundred employees who provide care and support for, on 
average, one hundred and seventy patients and their families. These hospice patients reside in 
three rural and one suburban county in Southwestern North Carolina. Patients receive end of life 
care in a variety of settings including hospice inpatient units at one of two hospice houses, long-
term care facilities, assisted living facilities, group homes and private residences within the 
service area. The LTC facility, owned by a large, multi-state healthcare organization, provides 
skilled nursing for patients with both rehabilitation and residential needs. These two agencies 
have a long-standing relationship of collaboratively providing care for patients with specialized 
nursing needs who are nearing the end of life. 
 At the start of the DNP project implementation phase, thirteen hospice patients were 
residing in the participating LTC facility. Additional patients joined the project at the time of 
their admission to hospice services. Data collection on the number of medications prescribed in 
the seven identified categories was suspended at the time that the patient left hospice services 
either through death, live discharge, or transfer from the LTC facility. 
Intended Outcomes  
 Short-term goal. The project intervention provided a short-term goal of educating the 
LTC facility’s pharmacist and providers on the benefits of deprescribing for patients under 
hospice care who reside in LTC. The educational session was developed based on a growing 
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body of evidence found in the literature that demonstrates improvement in the quality of life for 
patients with a reduced pill burden at the end of life. As part of the educational session, the 
participants were shown online tools that can be used to develop a systematic approach to 
deprescribing unnecessary, inappropriate, or harmful medications for hospice patients.   
Intermediate goal. An intermediate outcome for this DNP project was the demonstration 
of a reduction in the number of medications prescribed to hospice patients residing in LTC. A 
multidisciplinary, interagency collaboration between the facility pharmacist, hospice RN and 
DNP student provided recommendations for facility prescribers regarding appropriate 
deprescribing of drugs for each hospice patient. The targeted medication categories reviewed 
included vitamins and supplements, statins and cholesterol-lowering medications, anticoagulants 
and antiplatelet medications, cognitive-enhancing drugs, antihypertensives, medications for the 
management of diabetes, and medications for the management of gastrointestinal reflux disease.  
Long-term goal. The most significant outcome of this project was the long-term goal of 
improving the quality of life for patients under hospice care who reside in the LTC facility. 
Although the measurement of this outcome was beyond the scope of this project, achievement of 
this goal will become evident through a reduction in premature death, fewer ADEs, and the LTC 
facility hospice patient’s perception of improved quality of life over time. Another benefit of this 
project for the participating agencies will be realized over time as well, with financial gains 
associated with reduced healthcare costs related to fewer ADEs and actual savings related to 
fewer medications to purchase and dispense. For the hospice organization, there is the potential 
for additional cost-savings with their contracted pharmacy provider related to a stronger 
negotiating position for lower contractual per diem rates as a result of a reduction in medication 
usage.  
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Findings  
           For the project intervention, a pre- and post-education tool was completed by each of the 
four participants. There were five questions included on each tool to elicit the participant’s 
understanding of and attitudes toward medication reduction for hospice patients. Participants 
were asked to identify the ideal number of medications they would prescribe to hospice patients 
and the likelihood that the prescriber would discontinue medications for this patient population. 
The data collection tool included a question on the participant’s willingness to deprescribe 
medications for hospice patients in seven specific categories and whether they currently use an 
evidence-based tool for deprescribing. The final question sought to quantify the prescriber’s 
opinion regarding the number of medicines the prescriber would discontinue at one time (see 
Appendix I & Appendix J).  
           The pre-educational tool revealed that 50% of the participants considered 1-5 medications 
prescribed to a hospice patient to be ideal. The remaining 50% believed the best number to be 6-
10 medications. Each participant reported a willingness to deprescribe medications for hospice 
patients as either somewhat likely (50%) or very likely (50%). Before the educational session, all 
participants reported that they would deprescribe medications for gastroesophageal reflux disease 
(GERD), hypertension, and diabetes in their hospice patients, and 75% of participants would stop 
vitamins and supplements, cholesterol-lowering medications, anticoagulants or cognitive-
enhancing medications. Half of the participants reported current use of evidence-based 
guidelines or tools for deprescribing. The final question of the pre-educational tool showed that 
each participant had a different idea on the number of medications that should be stopped at a 
time- with 25% of the participants choosing 1-2 medications, another 25% chose 3-4 drugs, 25% 
DEPRESCRIBING FOR HOSPICE PATIENTS IN LONG-TERM CARE                           63 
would prefer to discontinue 5-6 medicines at one time, and finally, 25% of participants would 
deprescribe more than six medications at a time (see Figure 6.1).             
Figure 6.1.    
 
Figure 6.1. Data analysis for participant responses before and after the educational intervention 
on deprescribing. There were four participants, each of whom completed both a pre-education 
data collection tool and a post-education tool. The educational intervention demonstrated a 
change in participant opinions on the ideal number of medications prescribed to hospice patients 
residing in LTC and the use of an evidence-based tool for deprescribing decision-making. All 
other responses remained unchanged.  
In comparison, the post-education data collection tool revealed a change in the 
participant’s view of the ideal number of medications prescribed to hospice patients, with 75% 
reporting that number to be 1-5 medications, and 25% of participants reporting 6-10 medicines 
as the ideal number. There was no change in the likelihood of participants deprescribing, with all 
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participant’s willingness to deprescribe medications in seven specific categories remained 
unchanged after the educational session, and 100% of participants indicated that the evidence-
based tools and guidelines presented in the educational session would be helpful in the 
deprescribing process. Finally, participant’s views on the appropriate number of medications to 
deprescribe at any one time remained unchanged from the pre-education survey (see Figure 6.1). 
The DNP student collected outcomes data at the onset of the implementation period 
before the educational session, then at regular intervals every two to three weeks after that until 
the conclusion of the project implementation three and one-half months later. This data looked at 
the number of medications prescribed in each of the seven specified categories to each hospice 
patient residing in the LTC facility. Thirteen hospice patients were living in the LTC facility at 
the start of the project implementation. Throughout the project implementation, seven additional 
LTC residents came under hospice services. The DNP student collected data on a total of 20 
patients; however, only seven of the patients remained in the project from implementation to 
conclusion (see Appendix K).  
The DNP student analyzed data for each hospice patient looking at the number of 
medications per patient in each of the seven target categories and as an aggregate M of medicines 
prescribed per patient in all categories combined at the interval data collection points. There 
were six points of data collection- one initial, four intermediates, and the final data collection. 
The least number of medications prescribed to a patient in the seven combined categories at any 
point during project implementation was zero, and the highest number was seven. The mean (M) 
was 2.4 prescriptions in the target categories per hospice patient overall. The initial data 
collection point showed a M of 2.5 prescriptions per patient, with higher numbers seen at 
intermittent data collection points two and four, which correlated with new hospice admissions 
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or changes in patient condition. The peak M of any one of the data collection points was 2.8 
prescriptions per patient. Data collected in the last month of the three- and one-half-month 
project implementation demonstrated the lowest number of targeted medications, with a M of 2.1 
prescriptions per patient at the end of the project implementation (see Figure 6.2).  
Figure 6.2.  
 
Figure 6.2. M number of medications prescribed per patient at each of the six data collection 
intervals. Spikes in the M number of prescriptions reflect the addition of new patients to the 
project, before medication review and deprescribing. Overall there was a 16% reduction of 
medications from pre-intervention data collection point 1 to the final data collection point 6. 
From the peak M at data collection point 4 to the lowest M at data collection point 6, there was a 
25% reduction in the average number of medications prescribed in the seven target categories.  
Finally, looking at individual medication usage, the data revealed that all but one patient 
demonstrated a net reduction or maintenance of the current number of medications in the seven 
target categories. Thirteen of the twenty LTC patients under hospice services during the project 
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65% of the patients. Fifteen percent of the patients, for a total of three patients, had a net loss of 
one target medication. Two of the hospice patients residing in LTC, or 10% of the patients, had a 
net reduction of three prescriptions throughout their time in the project. One patient, or 5% of the 
total of patients whose medications were analyzed, had a net reduction of five medicines, while 
another 5% had an increase of two prescriptions (see Figure 6.3).   
Figure 6.3.  
 
Figure 6.3. This pie graph shows the net change in the number of medications prescribed to each 
of the 20 hospice patient participants in the seven target categories. 1. Dark blue represents 5% 
of patients participating in the project (n = 1) who had a reduction of five medications. 2. Red 
shows that 65% of patients (n = 13) neither increased nor decreased the number of prescribed 
medicines during the project implementation. 3. Green represents a net reduction of 1 medication 
for 15% of patient participants (n = 3). 4. Purple shows that 10% of patients (n = 2) were taking 
two fewer medications at the end of the project implementation. 5. Light blue signifies 5% of the 
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Summary 
            The foundation of this project was the educational intervention provided to the facility 
pharmacists, physician, and nurse practitioner. The DNP student presented evidence-based 
research to support the benefit of deprescribing unnecessary, inappropriate, or harmful 
medications for hospice patients who live in LTC. The DNP student, together with the LTC 
facility pharmacist and hospice RN met regularly to review medications and make 
recommendations for deprescribing to the facility providers in the seven target medication 
categories. Data were collected at the onset of the project and every two to three weeks until the 
conclusion of the project implementation phase three and one-half months after implementation.  
 The short-term goal of the project, to educate the pharmacists and providers for hospice 
patients regarding the evidence supporting the appropriate deprescribing of unnecessary 
medications for patients nearing the end of life, was achieved through one collaborative 
educational session. The project participants achieved the intermediate goal of medication 
reduction through biweekly interdisciplinary medication reviews for each hospice patient living 
in the facility. Data support the efficacy of the project intervention through the overall reduction 
of the number of medications prescribed in the targeted categories for hospice patients residing 
in LTC. Finally, and most importantly, the long-term goal of improved quality of life for this 
patient population will be demonstrated over time, as will the financial benefits realized by both 
the LTC facility and hospice provider related to reduced costs from ADEs and unnecessary 
expenses.  
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Chapter Seven: Implications for Nursing Practice 
The American Association of Colleges of Nursing (AACN) has developed competencies 
that define the criteria for the achievement of a doctoral degree in nursing. The essentials of 
doctoral education for advanced practice nursing (AACN, 2006), or DNP Essentials, outline 
eight categories of foundational outcomes for which all candidates for the Doctor of Nursing 
Practice (DNP) degree must exhibit mastery. Together with the successful completion of the 
academic components of the curriculum, the DNP project provides a tangible demonstration by 
the student of competency in each of the eight areas. This DNP project encompasses elements of 
each of the eight competencies contained in the DNP Essentials.    
Practice Implications 
             Essential I: Scientific underpinnings for practice. The first Essential speaks to the 
foundations of science and nursing theory that drive advanced practice nursing (AACN, 2006). 
The scientific underpinnings of the DNP nurse’s practice include the integration of knowledge 
from multiple disciplines to develop innovative ways to provide nursing care to people of all 
ages and health states (AACN, 2006). The DNP prepared nurse integrates new ideas into care 
models and evaluates the effectiveness of their outcomes (AACN, 2006).  
 There is a substantial body of research regarding the benefits of deprescribing for patients 
who are nearing the end of life, particularly for those residing in LTC facilities. Multiple 
disciplines contribute to this body of research, including nursing, medicine, pharmacy, and 
behavioral sciences. The integration of this knowledge and dissemination to a multidisciplinary 
team within the LTC facility was the foundation of this DNP project and the project intervention. 
The effectiveness of the project intervention was evident in the outcomes data, which showed a 
reduction in unnecessary, inappropriate, or harmful medications for this specific patient 
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population. Everett Rogers (1995) was a behavioral scientist whose theory of the diffusion of 
innovations was the foundation for this project. Together with Kurt Lewin’s theory on planned 
change (Oberleitner, 2019), the theory of diffusion provided the framework for integrating a 
change in the prescriptive practices of the LTC facility’s providers and the pharmacist. 
             Essential II: Organization and systems leadership for quality improvement and 
systems thinking. This core competency requires that the doctoral-prepared advanced practice 
nurse (APN) work within health systems and organizations to drive new models of care and 
practice improvements with a broader focus on community and population health (AACN, 
2006). The DNP nurse leader demonstrates the integration of improved health outcomes and 
patient safety with a reduction in healthcare disparities through the synthesis of newly developed 
research to create change in organizational strategies and health care policies (AACN, 2006). 
Quality improvement is the mainstay of the DNP nurse’s practice. It is the foundation of the 
APN’s advocacy for health care improvements that impact all aspects of a healthcare system, 
including business and economics. 
 This project was a multidisciplinary, interagency quality improvement project designed 
to influence the prescribing practices of providers and pharmacists within the LTC facility. The 
patient population for this project, namely hospice patients living in LTC, is a vulnerable and 
complex group. This quality improvement project included a newly developed process for 
deprescribing and collaboration across multiple disciplines to affect policy and outcomes for 
both participating agencies. The DNP student demonstrated leadership in developing a quality 
improvement project that can be adapted and applied to other vulnerable populations.  
             Essential III: Clinical scholarship and analytical methods for EBP. According to the 
DNP Essentials (AACN, 2006), the ability to synthesize research and integrate knowledge into 
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practice is the third foundational competency of the graduate of a DNP program. The DNP nurse 
looks to the nurse-researcher for the cultivation of new knowledge within the nursing discipline, 
then translates that insight into evidence-based guidelines and practices (AACN, 2006). The 
doctoral-prepared nurse seeks to incorporate appropriate research from other disciplines that 
provide support for effective change and improved patient outcomes. Mastery of this Essential 
includes the ability to discern reliable research using analytics, develop quality improvement 
projects based on the evidence of credible research, evaluate outcomes through data analysis, and 
work collaboratively across multiple disciplines (AACN, 2006).  
 The literature search for this project revealed a large and growing body of research and 
new knowledge regarding the benefits of medication reduction for patients nearing the end of 
life, particularly those who reside in LTC. The project intervention and subsequent outcomes are 
a direct result of the author’s ability to analyze the current research. Using interdisciplinary 
theories on change and dissemination of new ideas, the author created a successful quality 
improvement project that led to improved outcomes for the patients and the participating 
organizations.  
             Essential IV: Information systems/technology and patient care technology for the 
improvement and transformation of healthcare. This is the age of the information 
superhighway with information disseminated using a multitude of platforms. Protection of 
sensitive information, including personal health information (PHI), is the basis for the United 
States Department of Health and Human Services [HHS] (n.d.) policy on the Health Insurance 
Portability and Accountability Act of 1996 (HIPAA). The doctoral-prepared nurse must be 
proficient in the use of technology to provide patient care and promote improvement in 
healthcare across the delivery spectrum while maintaining patient confidentiality and safety 
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(AACN, 2006). The DNP nurse-leader must understand how to use technology to analyze and 
synthesize research and be innovative in the delivery of healthcare through a variety of 
technological modalities (AACN, 2006). The DNP nurse must demonstrate mastery of 
technology to perform data extraction from databases with accuracy and timeliness (AACN, 
2006). 
 The use of information systems and technology was inherent in this project. The author 
used a variety of information to conduct a literature search. The project intervention was 
developed using technology and presented via PowerPoint to the project participants. Outcomes 
data were collected from the hospice electronic medical record and stored electronically using 
safeguards for the maintenance of patient privacy. Data were analyzed using technology for 
evaluation of the effectiveness of the project intervention and to reinforce newly developed 
prescribing practices. Finally, the DNP student disseminated outcomes to project participants and 
the two participating organizations using web-based platforms for virtual meetings. 
             Essential V: Healthcare policy for advocacy in healthcare. Policy formation at every 
level of healthcare, from international organizations and the federal government to health 
systems and community programs, provides a framework for the delivery of care (AACN, 2006). 
The DNP curriculum prepares the APN to be a leader in the assessment of policy effectiveness, 
the development of policy changes or new policies to meet the needs of the community, and the 
implementation of these policies (AACN, 2006).  The DNP nurse leader is active in speaking out 
for social justice, advocating for equity and a reduction in disparities of healthcare delivery, and 
influencing the regulatory and financial policies that drive healthcare delivery (AACN, 2006). 
DNP graduates participate in policy formation at all levels and are proactive in providing a 
bridge between research and practice (AACN, 2006).   
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 The DNP project on deprescribing of unnecessary, inappropriate, or harmful medications 
for hospice patients residing in LTC is an example of the synthesis of research into practice. 
Well-constructed quality improvement projects lead to policy changes that improve outcomes 
and the quality of life for this vulnerable population. This project meets goals and mandates set 
forth by the Federal Government in Healthy People 2020 to reduce the number of inappropriate 
medications used by the elderly and disabled (HHS, 2019). The DNP project drives a change in 
practice and demonstrates the need for policy change at both the local and organizational levels 
for hospice and the LTC facility. Outcomes data for this project show a significant reduction in 
the number of unnecessary medications through appropriate deprescribing, which translates to 
costs savings and promotes policy change at the federal level to mandate medication reviews by 
multidisciplinary teams for patients receiving the Medicare hospice benefit.    
             Essential VI: Interprofessional collaboration for improving patient and population 
health outcomes. Healthcare in the United States is a highly sophisticated, complex system that 
requires collaboration with professionals from many disciplines to achieve optimal patient 
outcomes. Training for the DNP prepared nurse includes effective communication that empowers 
the APN to provide input and leadership for multidisciplinary, interprofessional healthcare teams 
(AACN, 2006). Evidence-based guidelines and standards of practice provide the framework for 
interdisciplinary collaboration, and the DNP nurse leader applies those tools both as a participant 
and leader in healthcare delivery. The DNP curriculum prepares the APN to navigate complex 
health systems effectively and lead others to develop necessary changes to policy and practice 
(AACN, 2006). 
 Interdisciplinary collaboration is the foundation of this DNP project. The project 
intervention was an educational presentation for providers who had prescriptive authority over 
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the hospice patients residing in their LTC facility and the pharmacist who was responsible for 
regular medication reviews. The DNP student’s ability to engage with project participants and 
effectively communicate the benefits of the project were foundational to the willingness of the 
providers to change prescribing practice patterns. The facility pharmacist was a key project 
participant, and regular multidisciplinary sessions were pivotal in achieving positive outcomes 
for deprescribing. It was also essential that the DNP student worked effectively with the 
administration of the LTC facility and senior leadership of the hospice organization. This DNP 
project a collaborative effort, with cooperation and coordination between the clinical DNP 
candidate and a DNP leadership student to achieve successful outcomes. The DNP student 
demonstrated effective leadership and communication skills while overcoming challenges found 
inherent in the project design and from external changes that affected the project plan.  
             Essential VII: Clinical prevention and population health for improving the nation’s 
health. The curriculum for the DNP graduate includes training to provide leadership in the areas 
of health promotion and disease prevention for individuals, specific patient populations, and the 
general public (AACN, 2006). The integration of scientific knowledge of population health 
based on epidemiology, biostatistics, and the environment provides the DNP prepared nurse 
leader with the skills to address cultural diversity and healthcare disparities in a meaningful and 
effective manner (AACN, 2006). The DNP curriculum prepares the APN to approach health care 
from a global perspective that addresses the needs of the individual while improving the health 
of the general population or that of specific groups within society (AACN, 2006).  
 This project focused on improving the health of a specific patient population, namely 
hospice patients who reside in LTC facilities. The principals of health promotion and disease 
prevention are central to the concept of deprescribing. Yet, providers do not universally 
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incorporate medication reduction into their prescriptive practice in the United States. While the 
LTC facility used some of the elements of this quality improvement project before its 
implementation, the addition of an interdisciplinary team to review medications was pivotal in 
the successful outcomes of this project. The DNP project achieves the goal set out by the HHS 
(2019) in Healthy People 2020 to reduce unnecessary medications for elderly citizens with 
disabilities. The project also aligns with the IHI (2019b) triple aim for improving population 
health through lower healthcare costs, improved population outcomes, and increased patient 
satisfaction with their healthcare experiences. The DNP project met these population health goals 
using a model that can be duplicated and expanded to other care delivery environments and 
different sub-populations.      
             Essential VIII: Advanced nursing practice. The discovery of new information through 
research, together with the depth and complexity of nursing science and knowledge, demands 
diversification within the field of nursing at the terminal degree (AACN, 2006). While there are 
foundational skills imparted to all APNs at the doctoral level, the volume of knowledge needed 
to practice at this level precludes the DNP nurse leader from mastery over all aspects of the 
discipline (AACN, 2006). The DNP curriculum includes elements of education that are common 
to all nursing disciplines, regardless of the specific specialty practiced by the student (AACN, 
2006). The doctoral curriculum equips APNs to perform comprehensive patient evaluations 
incorporating physical assessment for patients with complex illness and varying levels of 
wellness while considering social determinants of health and cultural diversity to develop 
appropriate plans of care (AACN, 2006). The DNP program equips the graduate to develop 
trusting partnerships with the patient and other healthcare professionals, optimizing patient 
outcomes and using the highest level of critical thinking and clinical judgment to provide 
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evidence-based care (AACN, 2006). The APN who achieves a doctoral degree serves as a 
mentor to nurses and healthcare professionals in other disciplines, provides education and 
guidance for the community, and influences policy at the local, statewide, and national level 
(AACN, 2006). 
 This project is a model for future quality improvement projects focused on medication 
reduction for patients residing in LTC while under hospice care. The outcomes data demonstrate 
the effective decrease of unnecessary medications, which leads to improved quality of life and 
reduced healthcare costs. There is an opportunity to expand the project model to include other 
sub-populations, including hospice patients living in different settings and the general population 
of LTC facilities. The interdisciplinary collaboration and effective communication established by 
this project serve to strengthen and streamline the delivery of healthcare for patients with 
complex illnesses. This model can be disseminated within the participating organizations and 
developed both statewide and throughout the nation.         
Summary  
        The elements of the DNP Essentials serve as a common thread for all nurses achieving their 
terminal degree, regardless of the candidate’s practice specialty.  This DNP project provides a 
tangible demonstration of the student’s mastery of the fundamental components of the DNP 
Essentials. This project is predicated on the use of evidence-based practice to guide quality 
improvement and thus influence policy change. The ever-evolving, complex healthcare system 
of today demands ongoing diligence and application of scientific principles and interdisciplinary 
collaboration.  The project has met the criteria outlined in each of the eight core competencies. It 
serves as a model for future expansion of the principal of appropriate deprescribing for 
populations beyond hospice patients residing in LTC.   
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Chapter Eight: Final Conclusions 
Education, communication, and collaboration were foundational elements of this DNP 
project. The project began with the education of LTC facility providers and pharmacists 
regarding the evidence supporting a systematic reduction of unnecessary, harmful, or 
inappropriate medications for patients who reside in LTC and are nearing the end of their life. 
Implementation of the project continued with the development of a multidisciplinary, 
interagency team consisting of the LTC facility pharmacist, the hospice NP/DNP student, and, 
later, the hospice RN who conducted regular medication reviews for hospice patients residing in 
LTC. This team provided recommendations for deprescribing unnecessary medications to the 
facility MD and NP who, if they agreed with the recommendations, would then discontinue 
medicines that were no longer appropriate. Data collection and analysis showed that this process 
was both practical and sustainable, even during the COVID-19 pandemic.   
Significance of Findings  
           As a result of the project intervention and subsequent establishment of regular medication 
reviews for hospice patients residing in LTC, the outcome goal of a ten percent reduction in the 
number of inappropriate medications was met and exceeded. This goal aligned with that of the 
Healthy People 2020 goal for a ten percent decrease in prescriptions for elderly adults with 
disabilities (HHS, 2019). Hospice patients, particularly those who reside in LTC, comprise a 
vulnerable population with complex health needs. Research is clear that fewer medications 
prescribed to patients at the end of life has a direct correlation to an improved quality of life, 
reduction in premature deaths, and decreased ADEs. This project achieved a 16% reduction in 
the M number of medications prescribed to hospice patients when comparing the initial data set 
to the final data set. When comparing the peak M of 2.8 medications per patient to the lowest M 
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of 2.1 prescriptions, there was a 25% reduction in the number of medications per patient in the 
target medication categories.  
 The educational session, in which the evidence-based benefits of a systematic reduction 
of unnecessary medications were presented, provided an opportunity to collect data on the 
current prescribing practices and attitudes toward deprescribing for the facility MD, NP, and 
PharmD. This education was foundational in the development of a collaborative, 
interdisciplinary team who made and implemented deprescribing recommendations. The pre- and 
post-educational session data collection tool provided insight into the effectiveness of the 
education. Providers and the pharmacist demonstrated an increased willingness to deprescribe 
using an evidence-based tool after the interventional session. Also, there was a shift in the project 
participant’s attitudes toward and understanding of the ideal number of medications prescribed to 
patients nearing the end of life.  
 Equally as important was the establishment of regular, multidisciplinary meetings to 
review medications and provide recommendations for discontinuation of unnecessary drugs. The 
inclusion of both facility and hospice employees offered a pathway for improved inter-agency 
communication and facilitated the dissemination of deprescribing recommendations to the 
facility providers. The outcomes data supported the effectiveness and importance of the 
medication review process. Since the conclusion of the project implementation, the facility 
pharmacist and hospice NP have continued to meet regularly to review medications for hospice 
patients and provide ongoing recommendations for deprescribing. The continuation of the 
medication reviews and subsequent recommendations for deprescribing demonstrates the 
sustainability of the process and the value in applying the same quality improvement process in 
other LTC facilities.  
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 The education and empowerment of facility and hospice nursing staff, which was the 
DNP project undertaken by a DNP leadership candidate in collaboration with this quality 
improvement project, was a pivotal element in the success of this undertaking. The collaborative 
nature of both projects underscores the benefit of a multidisciplinary approach to medication 
reduction for the welfare of the patient and the organization. Future quality improvement projects 
in LTC facilities must include both a clinical and leadership element for optimal implementation 
and success.   
Project Strengths and Weaknesses 
          Strengths. One of the greatest strengths of this DNP project was the passionate support of 
the LTC facility administrator. Because she believed in the value of deprescribing, she took on 
the role of the project lead. The corporation that owns the LTC facility required an employee of 
the organization to act as the lead and complete specific learning modules before the author 
could obtain project approval. Without the facility administrator’s support, this project would not 
have been possible.  
 Another strength of the project was its simple yet effective structure. The project design 
required only one intervention/educational session, which could be presented virtually if needed. 
Following the intervention, the project moved to regular medication reviews, a task already 
required of the facility pharmacist, and one that she whole-heartedly embraced. Regular 
medication reviews allowed recommendations to be developed in the natural course of the 
pharmacist’s workday without adding undue time burden or extra work for this very busy 
healthcare professional. The hospice nurse joined the medication review process as a result of a 
PDSA cycle that identified a need to have current information on the patient’s health status when 
making recommendations for deprescribing. The task of medication reviews was a part of the 
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hospice nurse’s regular workday as well. The COVID-19 pandemic hit after the education 
intervention was completed, and several medication reviews had been completed in person with 
the pharmacist and the hospice nurse and hospice NP. Once the pandemic limited access to the 
LTC facility, the DNP student met with both the facility pharmacist and the hospice RN virtually 
for medication review and development of deprescribing recommendations.  The cost of this 
project was minimal, but the benefits for the patient, the LTC facility, and the hospice agency 
both in terms of quality of life and cost savings have not yet been quantified or fully appreciated.  
 Weaknesses. One challenge of this project was the difficulty in gaining initial approval 
due to strict corporate policies at the LTC project site. Another weakness of this project was its 
dependence upon the willingness of the facility administrator and providers to embrace the 
importance of deprescribing. Finally, a notable weakness was the difficulty in establishing 
effective communication with the MD provider at the facility. Both the NP and pharmacist were 
responsive to electronic mail and cell phone text as well as virtual visits, but the physician 
communicated only in person. Once the COVID-19 pandemic struck in the middle of the 
implementation of the project, the DNP student was prohibited from going onsite. Thus, 
communication with the physician stopped.  
Project Limitations 
          Limitations to implementation and successful completion of this DNP project were 
minimal. As previously noted, the LTC facility chosen as the project site required an employee 
to function as the project lead. This created some difficulty in adhering to the pre-
implementation project timeline. The cost was minimal and included some printing costs for 
handouts and a modest budget for snacks during the educational session. The most significant 
limitation was the limited scope of the project and subsequent inability to demonstrate both 
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financial benefits for the organizations and the improvement of quality of life for the patient as a 
result of deprescribing.  
Project Benefits 
          The benefits of this project were many. The cost was minimal, the impact was high, and 
the time invested is part of the natural workflow for most of the participants. The process for 
medication review was efficient and streamlined. These simple interventions had a measurable 
impact on project outcomes. The development of an interdisciplinary and interagency team for 
medication review fostered improved collaboration and communication for the benefit of the 
agencies’ mutual patients. The target goal of a 10% reduction of unnecessary medications was 
successfully met and exceeded, providing adherence to goals set out in Healthy People 2020. The 
process of medication review is sustainable beyond the short implementation period. Finally, the 
project is easily reproduced in other LTC facilities.   
Practice Recommendations 
          The most exciting element of this quality improvement project is the potential to replicate 
it in each of the LTC facilities where hospice patients reside. The process of educating 
pharmacists and providers with prescriptive authority on the benefits of deprescribing is 
essential. Providers and pharmacists employed in LTC are experts in their field but may not have 
experience caring for patients at the end of life. This vulnerable patient population is complex 
with multi-morbid health issues and demands a careful examination of the risks and benefits of 
continuing previously prescribed medications. Also, the establishment of regular medication 
reviews and recommendations for the systematic reduction of unnecessary medications can be 
applied to vulnerable populations who are not yet under hospice care.  
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During the process of medication review, it became evident that the participation of the 
hospice RN was integral to the understanding of the patient’s condition and making appropriate 
deprescribing recommendations. Therefore, the bedside hospice nurse should be included in the 
multidisciplinary review of medications. In addition, concurrent education of the facility nurses 
by the DNP leadership student on deprescribing contributed to the success of this project through 
improved communication with patients, families, and facility providers regarding the benefits of 
eliminating unnecessary medications for hospice patients residing in LTC. Inclusion of the 
facility nursing staff in education on deprescribing and empowerment to discuss 
recommendations for medication reduction with providers, patients, and families is essential.  
This project was able to continue despite the disruption of the COVID-19 pandemic. 
Development of virtual presentations for educational sessions will assure that evidence-based 
practices on deprescribing can continue in the post-COVID healthcare climate.  Establishment of 
communication preferences for project participants is also essential. The inclusion of employees 
from both hospice and the LTC facility, as well as a variety of healthcare disciplines for 
medication review sessions, assures that recommendations for deprescribing are comprehensive 
and individualized. Finally, periodic analysis and dissemination of outcome data regarding 
medication reduction will validate the success of the project implementation. Furthermore, 
ongoing data analysis will contribute to future evaluation of the financial benefits and 
improvement in the quality of life for the hospice patient residing in LTC. 
Final Summary 
          Polypharmacy has been established as a risk factor for poor quality of life, increased 
ADEs, and increased suffering for patients nearing the end of life. Hospice patients residing in 
LTC are particularly vulnerable to the adverse effects of polypharmacy and inappropriate 
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medication use. The use of a systematic process for the elimination of unnecessary, 
inappropriate, or harmful medications for this patient population will reduce the risk of ADEs 
and improve quality of life. Providers for hospice patients in LTC may not have expertise in end 
of life care. They may not be aware of the growing body of literature that establishes the benefits 
of systematic medication reduction as patients near the end of life. The elimination of 
unnecessary medications benefits the patient through reduced pill burden, an improved sense of 
well-being, and avoidance of ADEs. Both hospice and the LTC facility benefit as well, through 
reduction in the cost of medications, reduced workload for the bedside nurse, and potential cost 
savings during contract negotiations with their pharmacy vendor as a result of fewer prescribed 
medications per patient.   
  Through the dissemination of evidence-based research on the benefits of deprescribing to 
facility providers, new prescriptive patterns can and will emerge for hospice patients. A single 
educational session, including facility providers and pharmacists, is sufficient to establish the 
foundation of deprescribing practices. Establishment of a multidisciplinary, interagency team for 
systematic medication review and communicating deprescribing recommendations to facility 
providers is essential to the successful reduction of unnecessary medications. Data should be 
collected periodically to demonstrate the effectiveness of the intervention. Each of these project 
elements can be accomplished through virtual visits, if needed, due to COVID-19. Also, the 
framework for this DNP project can be applied to vulnerable populations in other settings. For 
hospice patients who reside in LTC, quality of life, and reduction of the burden of polypharmacy 
are essential issues to address. Although the demonstration of improved quality of life for 
patients and cost savings for hospice and the LTC facility is beyond the scope of this project, 
research has shown that both are achieved through medication deprescribing to reduce 
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polypharmacy. The cost of this project was minimal, the impact of the outcomes was significant, 
and the benefit to the patients was priceless.                            
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Figure 1. PRISMA flow diagram for selection of references in the literature search. The initial 
search yielded 4,279 articles and publications. With the inclusion of the MeSH terms medicine, 
nursing, pharmacy/therapeutics/pharmacology, anatomy/physiology, biology, public health, and 
sciences, as well as criteria for scholarly/peer review, English language, and 5-year recency 
limit, the number of useful articles declined to 180. The author found18 articles through other 
sources, with 8 duplicate articles. Using titles and abstracts to determine relevance to the project, 
the author eliminated 143 articles. For the remaining 47 pieces, the author reviewed the full text 
for content related to generalized deprescribing, long-term care setting, and end of life status, 
excluding a total of twenty-six articles. Twenty-one articles met the criteria for inclusion in the 




































Additional records identified 
through other sources 
(n=18) 
Records after duplicates removed 
(n=190) 
Articles screened based on title 
and abstract 
Full text articles reviewed for 
eligibility                            
(n=47) 
Systematic reviews with meta-analysis, 
Controlled trial without randomization, 
Case-controlled/cohort studies, 
Systematic review of qualitative studies, 
Single qualitative/descriptive studies, & 




Full text articles excluded  
(n=22) 




DEPRESCRIBING FOR HOSPICE PATIENTS IN LONG-TERM CARE                           91 
Appendix B 
Table 1 




Article                                                           
Level of 
Evidence      
Data/Evidence Findings Conclusion or Summary
Use of Evidence in EBP Project 
Plan                       
Kua, C.-H., Mak, V. S. L., & 
Lee, S. W. H. (2018). 
Health outcomes of 
deprescribing 
interventions among older 
residents in nursing homes: 
A systematic review and 
meta-analysis. Journal of 





Level I Meta-analysis of randomized 
controlled trials (RCTs) 
conducted in LTC facilities 
with patients aged >59 showed 
deprescribing reduced the 
overall number of unnecessary 
medications by 59%. Using 
medication reviews to guide 
deprescribing reduced falls by 
24% and mortality by 26%. 
Deprescribing based on a 
structured medication review was 
shown to have significant benefits 
for older residents of LTC 
including reduced falls and 
premature death. More RCTs are 
needed assess effect of 
deprescribing specific medications 
and in populations with specific 
diagnoses and to assess impact on 
QOL, activities of daily living 
(ADLs) and cost savings. 
Robust meta-analysis which is the 
highest level of evidence. 41 RCTs 
with over 18,000 LTC residents aged 
60 or older were studied. This was not 
specific to end of life/hospice, but 
showed strong evidence that 
elimination of unnecessary 
medications reduces ADEs and leads 
to a reduction in healthcare costs. This 
is the foundation of the DNP project. 
Page, A. T., Potter, K., 
Clifford, R. & Etherton-
Beer, C. (2016). 
Deprescribing in older 




Level I Evidence of medication 
effects in older adults poorly 
studied (30-35% of study 
subjects >age 65. 98% of 
older adults have at least two 
chronic conditions. Frail older 
adults have highest risk for 
adverse drug events (ADEs). 
75% of older adults take 5 or 
more medications daily. 




Frequent medication review is 
necessary to ensure appropriate 
medication prescribing for older 
adults. Medications that are well 
tolerated may not be appropriate as 
people age. Medication reviews 
that align with patient goals of care 
lead to elimination of 
inappropriate/unnecessary 
medications. More high quality 
studies are needed to confirm 
current evidence that deprescribing 
is safe and "clinically relevant" for 
older adults (p. 131). 
This study offered the highest level of 
evidence and supports the benefits of 
medication reduction for older adults. 
The conclusion is a strong 
recommendation for systematic 
medication review for hospice patients 
in long-term care (LTC) and 
appropriate deprescribing- the very 
essence of this DNP project.
Farrell, B., Richardson, L., 
Raman-Wilms, L., de 
Launay, D., Alsabbagh, M. 
W., & Conklin, J. 
(2018). Self-efficacy for 
deprescribing: A survey for 
health care professionals 
using evidence-based 
deprescribing guidelines. 





Level III Development and use of a 
survey to explore the 
relationship between use of 
evidence-based deprescribing 
guidelines and deprescribing 
of specific drugs in long-term 
care. 
Use of evidence-based guidelines 
increases prescribers' self-
confidence in creating and 
implementing plans for 
deprescribing specific 
medications. 
The results of this study support the 
intervention being proposed to 
pharmacists and precribers in LTC 
facilities, namely use of an evidence-
based guideline to assist in appropriate 
medication reduction for hospice 
patients in LTC. 
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Level of 
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Data/Evidence Findings Conclusion or Summary
Use of Evidence in EBP Project 
Plan                       
Curtin, D., Dukelow, T., 
James, K., O'Donnell, D., 
O'Mahony, D., & Gallagher, 
P. (2019). 
Deprescribing in multi-
morbid older people with 
polypharmacy: Agreement 
between STOPPFrail 
explicit criteria and gold 
standard deprescribing using 
100 standardized clinical 





Level IV This case-control study used 
comparative markers to 
statistically correlate the 
Screening Tool of Older 
Persons' Prescriptions in Frail 
adults (STOPPFrail) tool for 
deprescribing inappropriate/ 
unnecessary medications at 
end of life to standardized 
cases. The STOPPFrail tool 
was found to have a positive 
predictive value of 89.3%, a 
strong correlation with the 
benchmark cases.          
The STOPPFrail tool was found to 
be an objective decision-making 
tool that eliminates barriers to 
deprescribing for older patients 
with advanced disease. The authors 
suggest that the tool can be used in 
place of a pharmacy medication 
review for patients with complex 
morbidity to identify medications 
that are appropriate for 
deprescribing. 
The STOPPFrail tool is emerging as a 
likely choice for inclusion in the 
toolkit binder that will be developed 
for the DNP project educational 
sessions for providers and 
pharmacists. This study is very relevant 
to the project due to its strong support 
of a decision-making tool that 
removes barriers to deprescribing. 
Limitations of the study include the 
use of theoretical case studies rather 
than actual patient charts. 
van der Meer, H. G., Taxis, 
K., & Pont, L. G. (2018). 
Changes in prescribing 
symptomatic and 
preventive medications in 
the last year of life in older 
nursing home residents. 




Level IV Retrospective multicenter 
cohort study conducted using 
pharmacy data for patients 65 
and older residing in LTC.  
Interventions included annual 
pharmacy review of 
medications.     
A lower number of preventative 
medications were prescribed at end 
of life (EOL) for elderly LTC 
patients in this study. The authors 
surmise that this may be due to an 
increased awareness of the futility 
of statin medications in light of 
terminal illness or very advanced 
age. There were fewer statins noted 
among study participants. 
This retrospective study suggests that 
awareness of the futility of 
preventative medications at EOL can 
lead to decreased pill burden due to 
deprescribing. This speaks to the need 
to advocate for an interdisciplinary 
system to review and reduce 
unnecessary medications in hospice 
patients who reside in LTC- which is 
the focus of this Quality Improvement 
DNP project.
Farrell, B., Pottie, K., Rojas-
Fernandez, C. H., Bjerre, L. 
M., Thompson, W., & 
Welch, V. 
(2016). Methodology for 
developing deprescribing 
guidelines: Using evidence 
and GRADE to guide 
recommendations for 




Level V Systematic review of 
qualitative literature to 
support development of an 
evidence based practice (EBP) 
guideline for deprescribing. 
Using an 8-step process, 3 
guidelines were developed for 
specific drug classes 




A systematic approach of 
development of guidelines for 
deprescribing ensures adherence to 
EBP. Specific drug classes were 
chosen based on risk/benefit 
profile. Algorithm tools were 
developed for each guideline to 
assist in the deprescribing process. 
Deprescribing is a complex 
undertaking, particularly for LTC 
residents at end of life. Development 
of EBP guidelines for deprescribing 
specific medication classes supports 
the goal of this DNP project, which is 
to provide education to  providers and 
pharmacists regarding polypharmacy at 
the end of life. Systematic guidelines 
assist practitioners with the 
elimination of unnecessary or harmful 
medications. Strengths include use of 
structured feedback during the 
development of guidelines. 
Limitations include lack of direct 
patient input in the deprescribing 
process. 
Jokanovic, N., Tan, E. C. K., 
Dooley, M. J., Kirkpatrick, 
C. M., Bell, J. S. (2015). 
Prevalence 
and factors associated with 
polypharmacy in long-term 
care facilities: A systematic 






Level V This qualitative systematic 
review revealed that 91% of 
residents in LTC take 5 or 
more medications and 65% 
take 10 or more. Using 
statistical analyses,  
polypharmacy was correlated 
to multiple comorbidities, 
symptoms of pain and dyspnea 
and recent hospitalization, 
cognitive decline, decreased 
function, number of 
prescribers  and length of stay 
in LTC.   
This systematic review 
demonstrates that older residents 
of LTC with multiple 
comorbidities are more likely to 
have polypharmacy and are at 
higher risk for adverse drug events 
(ADEs). 
This study informs the DNP project as 
it demonstrates a high correlation 
between older patients residing in LTC 
and polypharmacy. Additional risk 
factors are recent hospitalizations, 
functional disabilities, cognitive 
impairment and multiple comorbidity. 
Strengths of the systematic review 
include well-designed studies with 
clear inclusion criteria and the focus 
on frail, advanced aged residents of 
LTC.  
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Paque, K., Stichele, R. V., 
Elseviers, M., Pardon, K., 
Dilles, T., Deliens, L., & 
Christiaens, 
T. (2019). Barriers and 
enablers to deprescribing in 
people with a life-limiting 
disease: A systematic 




Level V Systematic review of 
descriptive studies on 
enablers and barriers to 
medication deprescriping for 
paitent's at the end of life. 




Five studies identified low 
organizational support and poor 
staffing as two significant barriers 
to medication deprescribing. Other 
barriers included poor 
communication skills, physician 
preferences to continue 
preventative medications and 
unclear patient goals of care.  
This systematic review was specific to 
older adults at the end of life and 
highlighted specific barriers and 
enablers to deprescrpibing. Some of 
the barriers can be overcome and are 
important considerations for this 
project. Physician preference was 
noted as a barrier and the educational 
presentation for the DNP project will 
share evidence based practice 
(EBP)and guidelines to deprescribing 
to assist LTC providers and 
pharmacists in appropriate medication 
reduction choices.  
Poudel, A., Yates, P., 
Rowett, D., & Nissen, L. M. 
(2017). Use of preventive 
medication in 
patients with limited life 
expectancy: A systematic 





Level V This qualitative systematic 
review looks at current 
evidence regarding use of 
preventative medications 
including statins, aspirin, 
antihypertensives, and 
osteoprosis meds in patients 
with limited life expectancy 
(LLE). 15 studies met the 
criteria including 3 in LTC. 
Patients with limited prognosis 
continue to receive medications 
for preventative or chronic 
conditions that may be of limited 
benefit. Rigorous studies are 
needed to develop guidelines 
specific to reduction of 
preventative medications for 
patients who are nearing the end of 
life.
This review further supports the aim of 
the DNP project- to offer providers 
and pharmacists evidence based 
guidelines and specific medication 
categories to consider stopping for 
patients who have LLE. 
Thompson, W., Lundby, C., 
Graabæk, T., Nielsen, D. S., 
Ryg, J., Søndergaard, J., & 
Pottegård, 
A. (2019). Tools for 
deprescribing in frail older 
persons and those with 
limited life expectancy: A 
systematic review. Journal 
of the American Geriatrics 
Society, 67(1), 172-180. 
doi:10.1111/jgs.15616
Level V Systematic review of 
qualatative studies assessing 
the use of deprescribing tools 
to guide appropriate 
medication reduction for 
older adults nearing EOL. 15 
tools were identified, but 
further research is needed to 
demonstrate a correlation 
between deprescribing, 
reduction in number of 
medications and improved 
outcomes.    
The availability of tools to guide 
the deprescribing process was the 
focus of this systematic review. 15 
tools were included with a variety 
of approaches to deprescribing. 
Tools focused on specific 
medications, comprehensive 
medication lists and frameworks 
for deprescribing.  
This study will help to inform my DNP 
project through the selection of a tool 
for use with deprescribing of 
inappropriate medications. Only four 
of the tools have been tested in 
clinical practice and correlations to 
improved outcomes and perceived 
QOL cannot be made without further 
RCTs. The strength of this study was 
the patient population that was used 
including frail, elderly patients at EOL. 
Todd, A., Husband, A., 
Andrew, I., Pearson, S.-A., 
Lindsey, L., & Holmes, H. 
(2017). 
Inappropriate prescribing of 
preventative medication in 
patients with life-limiting 
illness: A systematic 
review. BMJ Supportive & 




Level V The focus of this qualitative 
systematic review was the 
ongoing prescribing of 
preventative medications to 
patients nearing end of life. 
The Screening Tool of Older 
Persons' potentially 
inappropriate Prescriptions 
(STOPP) was utilized along 
with the Beer's criteria and the 
Unnecessary Drug Use 
Measure to assess for 
medication appropriateness 
specifically focused on 
statins, antihypertensives, and 
diabetic medications.  
The use of a systematic approach 
can assist practitioners to more 
easily assess for appropriateness 
of  medication use in patients 
approaching the end of life. There 
are several resources including 
STOPP criteria, Beer's list, and 
Medication Appropriateness 
Index/Unnecessary Drug Use 
Measure to assist in deprescribing 
decision making. EBP, supported 
by current research and literature 
review, supports the 
discontinuation of unnecessary, 
inappropriate and potentially 
harmful medicaitons in order to 
reduce ADEs and improve patient 
QOL.   
This research provides for tools to 
consider including in the DNP project 
for use by facility providers and 
pharmacists. Eliminating 
unnecessary/preventative medications 
is one of the expected outcomes of the 
project. Strengths of this study include 
a robust review of the literature with a 
unique focus on inappropriate 
preventative medication prescribing 
for patients at EOL. Limitations 
include the lack of a clear definition of 
preventative medications.   
DEPRESCRIBING FOR HOSPICE PATIENTS IN LONG-TERM CARE                           94 
 
Article                                                           
Level of 
Evidence      
Data/Evidence Findings Conclusion or Summary
Use of Evidence in EBP Project 
Plan                       
 Dees, M. K., Geijteman, E. 
C. T., Dekkers, W. J. M., 
Huisman, B. A. A., Perez, R. 
S G M., van 
Zuylen, L., . . . van Leeuwen, 
E. (2018). Perspectives of 
patients, close relatives, 
nurses, and physicians on 
end-of-life medication 
management. Palliative and 




Level VI Multicenter Qualitative Study 
using interviews with patients, 
relative, nurses, specialists 
and general practitioners. 
Focus of the study was 
perspectives regarding 
management of medications 
for patients nearing the end of 
life.
Perspectives on medication 
mangement at end of life varies 
among providers, patients and 
family members. This study 
informs the practice of 
deprescribing through 
demonstration of the need for 
clear communication to eliminate 
unnecessary medications at the end 
of life. 
The project plan is developed to 
facilitate proper medication selection 
for deprescribing. In addition, 
collaboration with the patient and 
family to identify goals of care and 
beliefs about appropriateness of 
medication reduction is foundational 
to evidence-based practice and will be 
encorporated in the tools and 
recommendations provided for 
assistance with deprescribing.  
McNeil, M. J., Kamal, A. H., 
Kutner, J. S., Ritchie, C. S., 
& Abernethy, A. P. (2016). 
The 
burden of polypharmacy in 
patients near the end of life. 





Level VI Observational secondary 
analysis of medications taken 
by patients with advanced 
illness. 47% of patients had a 
cancer diagnosis, mean age 
was 74 and average number of 
prescribed medications was 
11.5 at time of enrollment and 
10.7 at time of death/end of 
study.  Less than 7% of study 
participants took less than 6 
medications while 32.8% of 
participants took >14 
medications during the study.
Patients (n=244) at the end of life 
took a significant number of 
medications for management of 
chronic diseases unrelated to their 
terminal diagnosis or preventative 
medications such as vitamins and 
minerals. There is a pressing need 
for the development of systematic 
method of medication reviews and 
discontinuation of 
unnecessary/preventative 
medications for patients at end of 
life.   
This study supports the premise that 
patients nearing end of life remain on a 
significant number of medications 
unrelated to symptom management or 
their terminal disease process. 
Systematic reviews of medications 
with elimination of 
unnecessary/harmful/limited benefit 
medications will reduce the pill burden 
at end of life. 
Palagyi, A., Keay, L., 
Harper, J., Potter, J., & 
Lindley, R. I. (2016). 
Barricades and brickwalls- a 
qualitative study exploring 
perceptions of medication 
use and deprescribing in 







Level VI This single qualitative study 
looked at opinions regarding 
medication reduction from the 
perspective of the patient, 
family and health care 
providers using focus groups. 
Providers agreed to the 
concept of polypharmacy but 
were unmotivated to 
deprescribe, while patients 
and famlies were unaware of 
the the possible side effects 
associated with inappropriate 
preventative medication use. 
Nine focus groups were 
formed consisting of patients, 
staff, family members. 
Another group was formed 
with physicians and 4 
pharmacists. 
This study concludes that primary 
providers are central to successful 
medication reduction, with 
effective communication being at 
the core of its success. More 
education is needed both with 
prescribers, LTC facility staff, 
patients and their families. 
Pharmacists expressed that facility 
staff need further training to 
recognize, report and act upon 
ADEs when they occur.                                 
This study will inform the DNP 
project through inclusion of study 
results in the educational session, 
particularly in relation to physician 
communication with the patient and 
their surrogate decision makers, 
regarding rationale for deprescribing. 
Strengths of this study include 
inclusion of patients and family in the 
focus groups. Limitations include the 
small geographic area in which this 
study was conducted in New South 
Wales, Australia.                                                                                                                                                                                      
Paque, K., Elseviers, M., 
Stichele, R. V., Pardon, K., 
Vinkeroye, C., Deliens, L., 
…Dilles, T. 
(2019). Balancing 
medication use in nursing 
home residents with life-
limiting disease. European 




Level VI This is a single International 
qualitative study focused on 
risks and benefits of the use 
of preventative medications 
for patients residing in LTC 
who are nearing the end of 
life. The most commonly 
deprescribed categories were 
lipid-lowering medications 
(29%), followed by 
benzodiazepines (28%), 
minerals (21%) and 
antipsychotics (17%). 
This study used the Screening Tool 
of Older Persons' Prescriptions in 
Frail adults with a limited life 
expectancy (STOPPFrail) 
evaluation tool to assess for 
appropriate medications to 
deprescribe. Only 33% of patients 
had at least one inappropriate 
medication eliminated and the 
mean number of chronic 
medications increased over the 6-
month course of the study. 
This study showed that there was 
limited deprescribing through the 
course of the study and inappropriate 
medications remained as part of most 
patient's regimen. The STOPPFrail 
tool was used to evaluate medication 
lists but was not used to assist with 
deprescribing The message for this 
DNP project is to utilize a tool, such 
as the STOPPFrail, to assist with 
decision making and not just 
evaluations. 
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Schenker et al. (2019). 
Secondary analysis of a RCT 
looking at the impact of 
polypharmacy on symptom 
burden and QOL for patients 
with life-limiting illness 
nearing the end of life.
Level VI RCT that initially measured 
statin discontinuation was 
used for secondary analysis of 
the association between 
polypharmacy, symptom 
burden and QOL. Statistical 
correlations shown between 
high number of medications 
and higher symptom 
burden/lower QOL
Polypharmacy- defined as taking 
>4 medications or unnecessary 
medications, is particularly 
burdensome for elderly hospice 
patients, leading to low QOL and 
high symptom burden. 47% of 
patients included in this study were 
>74 years of age, and 35% were 
hospice patients. Patients who took 
the greatest number of medications 
had the most significant symptom 
burden and lowest quality of life.  
There was clinical signficance with 
higher number of medications and 
worsening symptom burden. Study had 
a component of hospice patients and 
the elderly and supports the 
foundational premise of this project, 
that reduced medication burden will 
lead to improved QOL. This was a 
secondary analysis which did not allow 
for determination of causation 
between polypharmacy and high 
symptom burden/low QOL. 
Conklin, J., Farrell, B., & 
Suleman, S. (2019). 
Implementing deprescribing 
guidelines into 
frontline practice: Barriers 
and facilitators. Research in 
Social and Administrative 
Pharmacy, 15(6), 796-800. 
doi:10.1016/j.sapharm.201
8.08.012
Level VII This article was written 
following the Bruyere 
Evidence-Based 
Deprescriging Guideline 
Symposium that convened in 
March, 2018. 107 participants 
engaged in an interactive 
discussions to identify factors 
which block or facilitate use 
of deprescribing guidelines in 
clinical practice.
For deprescribing to be successful, 
practitioners must include patients 
and their families in the decision-
making process. This is a 
foundational component of 
evidence-based practice. In 
addition, there must be a culture 
change that supports systematic 
reducation of medications. 
Deprescribing must become an 
integral part of conversations and 
evaluations at every level from 
providers to patients and 
caregivers. 
Expert opinion paper that undergirds 
the premise of this DNP project- to 
work collaboratively and 
systematically in partnership with 
providers, pharmacists, patients and 
families to reduce unnecessary 
medications, improve outcomes and 
enhance quality of life for hospice 
patients residing in LTC.
Garfinkel, D., Ilhan, B., & 
Bahat, G. (2015). Routine 
deprescribing of chronic 
medications to 
combat polypharmacy. 
Therapeutic Advances in 
Drug Safety, 6(6),212-233. 
doi:10.1177/20420986156
13984
Level VII Expert opinion article on the 
need to reduce inappropriate 
medication use (IMU) and 
polypharmacy for the most 
frail and medically complex 
patients. There were four 
areas of emphasis for care of 
very old age, complex 
comorbid, dementia, frail and 
limited life expenctancy 
(VOCODFLEX) patients.
Polypharmacy includes even one 
inappropriate or harmful 
medication. Reduction of 
polypharmacy contributes to 
decreased adverse drug events and 
improved quality of life for 
VOCODFLEX patients. Guidelines 
are emerging that effectively 
reduce IMU. 
Supportive opinion that seeks to 
change the culture of multiple 
medication use and fosters critical 
assessment of medication regimens 
for the selected patient population for 
this DNP project. 
McGrath, K., Hajjar, E. R., 
Kumar, C., Hwang, C., & 
Salzman, B. (2017). 
Deprescribing: A 
simple method for reducing 
polypharmacy. Journal of 
Family Practice, 66(7),436-






Level VII Expert opinion with case 
studies highlighting the 
challenges of medicaiton 
reduction for multimorbid 
patients. A step-wise process 
is used to eliminate 
unnecessary, harmful or 
inappropriate medications. 
The desired outcome is a 
reduction in adverse drug 
events (ADEs) and improved 
functional capacity for 
patients with complex disease 
processes. 
Effective discontinuation of 
medications requires a systematic 
process that includes the patient or 
surrogate decision maker. Case 
studies provide suggested dialogue. 
Medication classes are reviewed 
and critiqued for risk/benefit of 
deprescribing. Patient and provider 
barriers examined and addressed.
This is a helpful article to address 
concerns and offer models for 
overcoming barriers commonly 
encountered with deprescribing. It will 
inform the DNP project by offering 
anticipatory guidance in addressing 
barriers to describing that may be 
encountered with both patients and 
providers. 
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Mangin, D., Bahat, G., 
Golomb, B. A., Mallery, L. 
H., Moorhouse, P., Onder, 
G., . . . Garfinkel, D. (2018). 
International group for 
reducing inappropriate 
medication use & 
polypharmacy (IGRIMUP): 
Position statement and 10 
recommendations for 
action. Drugs & 
Aging, 35(7), 575-587. 
doi:10.1007/s40266-018-
0554-2
Level VII International expert opinion 
statement offering action 
items bsaed on current 
guidelines as well as 
indentifying gaps in research 
for polypharmacy and 
medication reduction. This 
group consensus focused on 
the need for appropriate 
guidelines for deprescribing 
for patients with complex 
illness and multiple 
morbidities. 
Polypharmacy contributes to 
increased morbidity and mortality, 
yet current guidelines are not 
derived from research based on 
patients with multiple comorbid 
conditions. Ten action points were 
developed to individualize 
guidelines for the most complex 
patients. In addition, 12 
recommendations for research to 
address gaps in current knowledge 
were offered including tools for 
evidence-based guidelines (EBG 
for multimorbid patients.
The population that this DNP project 
targets are frail, debilitated and 
multimorbid patients who are nearing 
the end of life and reside in LTC. This 
statement highlights the challenges 
faced in applying current EBG 
developed for single-disease patients 
to patients with complex illness. An 
awareness that adjustments to 
accommodate multiple morbidities 
must be considered will contribute to 
the success of the project and 
ultimately reduction of unnecessary, 
inappropriate or harmful medications 
in the target population.
World Health Organization. 
(n.d.). The third WHO 
global patient safety 
challenge: Medication 




Level VII The World Health 
Organization (WHO) issued 
their third Global Patient 
Safety Challenge which 
focuses on reducing harm 
caused by medications. It is a 
call to reduce avoidable 
adverse effects from 
medications by 50% world-
wide over 5 years. Offering a 
four-part strategic framework 
for implementation of action 
areas.
This Patient Safety Challenge was 
initiated in 2017 and 
comprehensively addresses aspects 
of polypharmacy that place all 
people at risk for harm. The WHO 
campaign targets patients, 
healthcare providers, 
pharmaceutical companies and 
health systems and calls for a  
fundamental culture change that 
will reduce ADEs and manage risks 
of polypharmacy. 
The WHO's global Patient Safety 
Challenge calling for reduction of 
polypharmacy to improve quality of 
life and mitigate risk of ADEs is 
reflective of the values inherent in this 
DNP project. Risk reduction, 
avoidance of harm, improvement in 
quality of life and shared decision-
making are the focus of this project, 
which meets the goals of this 
initiative. 
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Figure 2.    Roger’s Theory of Diffusion of Innovation 
 
 
Figure 2. Roger’s theory of diffusion of innovation includes a five-step innovation to diffusion 
process that occurs over time. The first step is awareness of a new idea, concept, or process. 
Next, through persuasion, attitudes change regarding the benefit of the new idea. The third step 
incorporates a decision to move forward with adopting the new idea or rejecting it. The fourth 
step is the implementation of the new process, idea, or concept. Early adopters are those that 
move quickly through the process and embrace the new idea with minimal effort. Late adopters 
take more time and energy to communicate the worth of adopting the new idea and incorporating 
it into their daily workflow. The final step involves confirmation of the benefit of adopting the 




• Awareness of new idea/concept
Step 2
• PERSUASION
• Attitude toward new idea/concept
Step 3
• DECISION
• Accept/reject new idea
Step 4
• IMPLEMENTATION
• Incorporation of new idea into daily work
Step 5
• CONFIRMATION
• Evaluate effectiveness/ongoing use of idea
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Figure 3.    Lewin’s Planned Change Theory 
 
Figure 3. Lewin’s planned change theory reflects a three-step process for systematic change. The 
first step is to unfreeze the status quo. For this DNP project, the first step was to create an 
awareness of the need to change prescribing practices for hospice patients residing in LTC 
through an educational session with providers and the pharmacist. The second step was to 
implement the planned change. Deprescribing tools and an electronic application were provided 
for project participants to assist with decision-making for appropriate deprescribing. The author 
communicated monthly with the providers and met biweekly with the pharmacist to address 
barriers to deprescribing, thus promoting acceptance and incorporation of the planned change 
into daily prescribing practice. The final step is to refreeze. This step occurs when the anticipated 
change, which was deprescribing of unnecessary, inappropriate, or harmful medications, 
becomes a part of the daily prescribing practices of the providers and is applied to all subsequent 




Deprescribe as            
appropriate
Refreeze








for patients at 
end of life
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Figure 4. Plan-Do-Study-Act (PDSA) cycle for quality improvement was completed every two 
to three weeks during the DNP project implementation phase. This framework for assessing 
change guided the continuous quality improvement process and addressed barriers to change. 
The plan was the desired outcome for the project- deprescribing of unnecessary, inappropriate, or 
harmful medications for hospice patients residing in LTC. The second phase, do, involved 
collecting outcomes data on the number of target medications prescribed to each patient at six 
data collection intervals. The study phase involved an analysis of the data to determine the 
effectiveness of the educational intervention to achieve appropriate deprescribing for this unique 
patient population. The final step in each PDSA cycle was to act on the evaluation of the data by 
reviewing deprescribing guidelines and tools with the pharmacist and providers employed by the 
LTC facility. Once the author addressed barriers to deprescribing, a new PDSA cycle began.   
• Periodic data mining 
using hospice EHR 
for patients residing 
in LTC/project site 
facility. 





prescribed to hospice 
patients 




• Review deprescribing 
guidelines and tools 
with 
providers/pharmacist
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Figure 5.          SWOT Analysis 
 
 
Figure 5. The SWOT analysis of the DNP project reflected internal strengths and weaknesses as 
well as external opportunities and threats to the success of the project. Strengths included the 
expertise of the author/presenter, a substantial body of evidence supporting the practice of 
deprescribing for this patient population, and the availability of tools to assist in the decision-
making process of deprescribing. Open access to data for analysis of outcome measures was an 
additional strength. Internal weaknesses included the time-consuming nature of the task of 
deprescribing and time constraints for the completion of the project and data analysis. The 
limited number of deprescribing tools for patients with complex illnesses and multiple 
comorbidities was an additional weakness. External opportunities included financial benefits to 
the hospice organization and the LTC facility in which the hospice patients reside. Pharmacists 
employed by the LTC facility provided expertise in recommending medications for 
deprescribing. Threats included the willingness of providers to incorporate another task into their 
busy practice and a reluctance to participate in the project education and follow up.   
Strengths
Author's expertise in hospice care
Scientific evidence supporting 
deprescribing
Tools available to streamline process
Access to data for analysis of 
outcomes
Weaknesses
Time constraints for project 
implementation and data collection
Time-consuming nature of the 
depresribing process
Limited deprescribing tools for 
patients with multiple comorbities 
and complex illness
Opportunities
Financial benefits/reduced costs for 
LTC facility
Financial benefits for hospice 
organization
Patient satisfaction and improved 
quality of life
Pharmacists available to recommend 
medications appropriate for 
depresribing
Threats
Addition of time-consuming task 
(deprescribing) into daily practice
Permission to hold educational 
session at LTC facility site
Ability to follow up with 
providers/pharmacist on site
Willingness of pharmacist/providers 
to attend educational session at 
alternative site (hospice)
SWOT
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Figure 6.   Hospice Letter of Approval 
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Table 2.     
 






Educational presentations    
Handout- bound 20 
       
$12.24  
        
$244.80  
Snacks for 12 participants  
 
                    













        $18.04 
 
        $ 7.66 
Total   
 
      $302.58 
 
Note. The budget for the DNP project included a bound handout for each participant at the 
educational session, as well as additional reference folders for the final project outcomes 
presentation to each facility and East Carolina University. The food budget was for light snacks 
offered during the educational session. Total mileage for the project was initially budgeted with 
nine trips at 1 mile each from home to hospice and eight trips from home to the LTC facility at 
1.4 miles each. The budget was revised after the COVID-19 pandemic led to restricted access to 
the LTC facility. The number of trips from home to hospice remained the same, but the author 
only made three trips from home to the LTC facility at 1.4 miles each.   
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Figure 7.    
 
DNP Project Participant Pre-Education Data Collection Tool: 
Medication Deprescribing at End of Life in the Long-Term Care Population 
 
1. Before participating in a collaborative educational session on deprescribing, what do you 
consider to be the ideal number of medications prescribed for a hospice patient?   
0 [   ]      1-5 [   ]      6- 10 [   ]      11-15 [   ]      > 15 [   ] 
 
2. Prior to participating in a collaborative educational session, how likely are you to deprescribe 
medications for patients who are currently under hospice care in your facility? 
Very unlikely [  ] Somewhat unlikely [  ] Neither likely/unlikely [  ] Somewhat likely [  ] Very 
likely [  ] 
 
3. Please indicate the categories of medications you would currently consider deprescribing for 
Hospice patients: 
Vitamins/supplements [  ]  
GERD medications [  ] 
Statins/cholesterol medications [  ]  
Anticoagulants [  ]  
Cognitive enhancing medications [  ] 
Antihypertensives [  ]  
Diabetic medications [  ] 
 
4. Do you currently utilize any tools or evidence-based guidelines for deprescribing? 
Yes [   ]   No [   ]    
 
5. Before participating in this educational session, how many medications would you be willing 
to deprescribe at the same time?  




Figure 7. DNP project participants completed the pre-education data collection tool before the 
start of the educational session. This tool helped to promote awareness of a need for change and 
to assess provider/pharmacist readiness for changing prescribing practice.   
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Figure 8.    
 
DNP Project Participant Post-Education Data Collection Tool: 
Medication Deprescribing at End of Life in the Long-Term Care Population 
 
1. As a result of your participation in this collaborative educational session on deprescribing, 
what do you consider to be the ideal number of medications prescribed for a hospice patient?   
0 [   ]      1-5 [   ]      6- 10 [   ]      11-15 [   ]      > 15 [   ] 
 
2. After participating in this collaborative educational session, how likely are you to deprescribe 
medications for patients who are currently under hospice care in your facility? 
Very unlikely [  ] Somewhat unlikely [  ] Neither likely/unlikely [  ] Somewhat likely [  ] Very 
likely [  ] 
 
3. Please indicate the categories of medications you would consider deprescribing for Hospice 
patients based on the existing body of knowledge and best practice guidelines presented in this 
educational session: 
Vitamins/supplements [  ]  
GERD medications [  ] 
Statins/cholesterol medications [  ]  
Anticoagulants [  ]  
Cognitive enhancing medications [  ] 
Antihypertensives [  ]  
Diabetic medications [  ] 
 
4. Do you feel the tools and guidelines for deprescribing presented today will be helpful in 
assisting you to reduce inappropriate or unnecessary medications for hospice patients under your 
care? 
Yes [   ]   No [   ]    
 
5. After participating in this educational session, how many medications would you be willing to 
deprescribe at the same time?  




Figure 8. DNP project participants completed the post-education data collection tool at the 
conclusion of the educational session. This tool evaluated the effectiveness of the educational 
session to raise awareness of the importance of deprescribing for hospice patients and 
provider/pharmacist willingness to engage in the process of medication reduction through 
deprescribing. 
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Table 3.  
 
Evaluation Tool for Outcomes Measurement 
 
 
Note. Excel spreadsheet developed to analyze outcome data and evaluate the success of the DNP 
project. Data were collected at the start of the project, at four intermediate points during 
implementation, and the conclusion of the project implementation phase. Data were analyzed to 
track the progress of deprescribing efforts throughout the project implementation. Outcomes data 
showed the changes in the number and types of medications prescribed/deprescribed for hospice 
patients residing in LTC in seven specific medication categories.  
Patient # Vitamins/Supplements Statins/cholesterol lowering Anticoagulants Cognitive Enhancing Antihypertensives Diabetic Medications GI Reflux Total
1 1 1 2
2 D/C 2/3/2020 0
3 D/C 1/19/2020 0
4 1 1
5 0
6 D/C 3/4/2020 0
7 D/C 1/18/2020 0
8 D/C 2/2/2020 0
9 1 1 1 3
10 1 1
11 2 1 3
12 D/C 4/13/2020 0
13 1 1
14 D/C 3/28/2020 0
15 1 1 3 1 6
16 1 1 2
17 D/C 3/31/2020 0
18 D/C 4/7/2020 0
19 D/C 4/18/2020 0
20 D/C 4/20/2020 0
Final Outcomes Data 4/20/2020
  
